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Microglia, the resident macrophages in the brain, play diverse roles ranging from 
surveillance and maintenance of the healthy brain to its protection upon an insult. However, 
several neuropathologies, including ischemia, involve a chronic activation of microglia 
which can lead to an excessive production of pro-inflammatory molecules that can 
exacerbate neurodegeneration.  
Activated microglia can resolve post-ischemic neuroinflammation and help in tissue repair. 
However, reperfusion, the current treatment for ischemic stroke, induces a chronic 
activation of microglia which can elicit excessive pro-inflammatory mediators, disrupt the 
blood brain barrier, and lead to the recruitment of infiltrating immune cells which 
altogether exacerbate neuroinflammation and worsen disease progression. Understanding 
regulation of microglial activation will aid in the development of therapeutic strategies that 
mitigate microglia-mediated neurotoxicity in neuropathologies, including ischemia. 
With an aim to investigate the epigenetic regulation of microglial activation in ischemic 
stroke, we chose to study histone modification Histone 3-Lysine 9-acetylation (H3K9ac) 
and its regulation in microglial activation. It was hypothesised that H3K9ac modulations 
determine the inflammatory response of microglia, by altering expression levels of pro- 
and anti-inflammatory genes in neuropathological conditions, including ischemic stroke 
and infection. H3K9ac levels were found to be upregulated in activated microglia 
distributed in the cortex, striatum, and hippocampus in response to ischemic stroke, in an 
experimental mouse model of middle cerebral artery occlusion (MCAO). A similar 
upregulation of H3K9ac was detected in lipopolysaccharide (LPS)-activated microglia in 
the Wistar rat brain, indicating that H3K9ac upregulation is consistently associated with 
microglial activation.  
XVIII 
It is well established that Histone Deacetylases (HDACs) regulate H3K9ac. Our findings 
indicate that HDAC inhibitor sodium butyrate (SB) mediates neuroprotection by 
epigenetically regulating the microglial inflammatory response. During cerebral ischemia, 
HDAC inhibition by SB downregulated the expression of pro-inflammatory mediators 
TNF-α and NOS2 in activated microglia, upregulated microglial IL10, and improved 
neuronal survival. Further in vitro analysis of SB treatment in activated microglia showed 
SB to decrease H3K9ac enrichment and transcription at pro-inflammatory (Tnf-α, Stat1) 
while upregulating H3K9ac enrichment and transcription at anti-inflammatory (Il10) gene 
promoter, further inducing the expression of genes downstream of the IL10/STAT3 anti-
inflammatory pathway. Altogether, these results show evidence of HDAC inhibition 
through SB being a promising molecular switch to epigenetically modify microglial 
behaviour for the treatment of microglia-mediated neuroinflammation in neuropathologies.  
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The brain is a complex organ, orchestrating bodily functions while maintaining an 
individual’s conscience and consolidated memory. Neurons, one of the major functional 
units of the brain, exert their functions with continual support from various glial cells, 
including astrocytes, oligodendrocytes and microglia during brain development, 
maintenance, and tissue repair (Auld and Robitaille, 2003, Cahoy et al., 2008, Nimmerjahn 
et al., 2005, Shigemoto-Mogami et al., 2014, Michell-Robinson et al., 2015) .  
Microglia, which are the specialized immune cell of the central nervous system (CNS),  
populate the brain during embryonic development as myeloid precursors from the yolk sac 
(Ginhoux et al., 2010). Microglia account for nearly 5-20% of the total glial population in 
the adult CNS (Lawson et al., 1990). Microglia play various roles and respond to delicate 
cues from astrocytes, oligodendrocytes, and most importantly the neuronal population 
(Miyamoto et al., 2015, Schafer et al., 2013). During development, microglia exhibit 
functions suited to the maturing brain, changing their functional phenotype from 
‘amoeboid’ cells with rounded morphology to a ‘ramified’ morphology with extended 
processes to suit the varying demands of organ development and neural maintenance 
during adulthood (Bilimoria and Stevens, 2015). In the adult brain, microglia constantly 
probe their environment with dynamic processes, and engage in synaptic pruning to 
maintain health of the neural network (Li et al., 2012b). In neuropathological conditions, 
microglial cells act as sentinels, and get activated in response to any insult to the brain 
parenchyma. They are poised to protect the brain by eliminating invasive pathogens and 
then carrying out post-injury repair. However, chronic microglial activation as seen in 
various neuropathologies, can exacerbate neurodegeneration and neurotoxicity (Block et 
al., 2007, Hellwig et al., 2013). To address microglia mediated neuroinflammation, it is 
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important to understand the regulation of microglial activation, and find avenues to 
modulate it for therapeutic benefit. 
The following review of current literature gives a brief update on the recent findings on 
microglial origin, their function in the developing, adult and aging brain, and microglial 
involvement in pathology with a focus on ischemic stroke. This is followed by a discussion 
of epigenetic mechanisms, which can be potential therapeutic targets to regulate microglial 





Over the last century, specific seminal studies have been crucial to the eventual 
identification of microglial origin and their cellular identity (Illustration 1-1) (Ginhoux et 
al., 2013). In the early 20th century, Rio-Hortega was the first to coin the term “microglia” 
in an attempt to differentiate these cells from other neuroectoderm originating cells such 
as neurons, astrocytes, and oligodendrocytes (Rio-Hortega, 1939). Rio-Hortega (Rio-
Hortega, 1939) extended  his mentor- Ramon y Cajal’s observation that these cells were of 
a mesodermal origin with phagocytic and migratory properties. The notion of the origin of 
microglia split into two major schools of thought: mesodermal and neuroectodermal origin. 
Over time, evidence for microglial mesodermal identity far outnumbered others that 
professed a neuroectodermal origin (Fujita and Kitamura, 1975, Kitamura et al., 1984, 
Fedoroff et al., 1997, De Groot et al., 1992, Matsumoto and Fujiwara, 1987). Some studies 
also suggested a subependymal (Lewis, 1968), or a pericytal origin (Mori and Leblond, 
1969, Barón and Gallego, 1972). In the lead up to validating the myeloid origin of 
microglia, certain studies suggested microglia to originate from circulating monocytes in 
the post-natal brain (Ling, 1976, Imamoto and Leblond, 1978, Ling et al., 1980, Ling, 
1979). Others confirmed the shared phenotypic homology between microglia and 
monocytes/macrophages with markers like F4/80, Mac-1, and CD11b (Perry et al., 1985, 
Morris et al., 1991, Wang et al., 1996) and their proliferative ability (Alliot et al., 1991). 
These studies further observed that macrophage-like cells from embryonic hematopoietic 
precursors migrate as early as embryonic day 12 (E12) and seed the brain parenchyma, 
before the start of bone marrow homeostasis. Meanwhile, a study involving PU.1, a 
transcription factor determining myeloid lineage, observed that PU.1 knock out (KO) mice 
lack microglial cells, thus, conclusively confirming the myeloid origin of microglia (Beers 
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et al., 2006). With studies detecting microglia-like cells as early as E8.5/E9.0 in the 
neuroepithelium of rodent embryos (Alliot et al., 1991, Alliot et al., 1999), the origin of 
microglial progenitors in the yolk sac (YS) was finally determined by a YS progenitor fate 
mapping  study (Ginhoux et al., 2010). The fate mapping study determined microglial cells 
to originate from E7.25 Runx1+YS derived hematopoietic progenitors (Ginhoux et al., 
2010). The precise phenotypic identity of microglial precursors was subsequently 
determined as being E8 primitive c-kit+ erythromyeloid YS precursors, which start as 
CD45+ c-kitloCX3CR1− cells, following which they migrate to the developing brain as 




Illustration 1-1 Timeline describing the studies that paved the way to determine the 
origin of microglia and the phenotypic identity of its precursors   
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 Function 
1.1.2.1 Developing brain 
The brain undergoes targeted changes in structural and functional organisation during 
development, from the early embryonic state to adulthood. Brain development during 
embryonic stages is marked by the differentiation of neural progenitor cells and the 
formation of the neural tube. This is followed by a critical stage of neural patterning in 
which neural progenitors migrate to specific brain locations and differentiate into mature 
neuronal subtypes based on spatial guidance cues (Grove and Monuki, 2013, Temple and 
Shen, 2013, Gauthier-Fisher and Miller, 2013). During fetal development, neuronal 
proliferation, migration, and differentiation are the main events, along with a regressive 
event that involves a drastic loss of neurons and synapses. Post-natal development of the 
brain is marked by synaptic exuberance (excessive synapse formation), accompanied by 
region-specific neurogenesis, gliogenesis, myelination (Stiles and Jernigan, 2010, Bandeira 
et al., 2009). This is followed by another regressive event in which excess astrocytes, 
oligodendrocytes undergo apoptosis, and substantial synaptic pruning takes place (Stiles 
and Jernigan, 2010). Microglial cells are seen to colonise the brain at early embryonic 
stages in mice suggesting an important role in the developing CNS. Indeed, recent studies 
point to microglia being important in neuronal patterning, neuronal death during regressive 
events, synaptic pruning and even mediating cell survival and proliferation (Bilimoria and 
Stevens, 2015, Aarum et al., 2003, Squarzoni et al., 2015). 
Morphologically, microglia in the developing brain assume a rounded ‘amoeboid’ shape 
(Figure 1-1). A recent study in mice demonstrated that microglia mature in three temporal 
stages during brain development complete with distinct epigenetic and transcriptional 
profiles (Matcovitch-Natan et al., 2016). The stages were defined as early microglia (day 
E10.5-14), pre-microglia (day E14-P9) and adult microglia (4 weeks onwards). Gene 
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ontology analysis revealed early microglia to express predominantly, genes involved in 
defence response and multiple hematopoietic fates along with those associated with cell 
cycle and proliferation. On the other hand, pre-microglia expressed genes associated with 
neural migration, neurogenesis, and cytokine secretion while adult microglia expressed 
genes related to tissue maintenance (Matcovitch-Natan et al., 2016, Rangarajan et al., 
2012). 
In context of the function of early and pre-microglia, evidence of microglial involvement 
in brain patterning and cortical wiring came from the uneven distribution of microglia in 
the regions in the brain. Regions such as the corpus callosum and the external capsule in 
the early mouse brain, also termed as ‘hotspots’, showed enriched presence of microglia. 
These regions were implicated to be important guideposts in axonal guidance and cellular 
migratory paths during neural migration (Squarzoni et al., 2014, Swinnen et al., 2013). 
Additionally, microglia also accumulate in the proliferative zone of the cortex, where they 
control the size of the neuronal precursor population (Cunningham et al., 2013, Arnò et al., 
2014)  
Programmed cell death in neurons, along with synaptic exuberance and pruning are critical 
events in postnatal brain development (Stiles and Jernigan, 2010, Bandeira et al., 2009). 
Studies show microglia to be involved in shaping the neuronal landscape by inducing 
apoptosis through CD11b/DAP12 signalling mediated production of reactive oxygen 
species (Wakselman et al., 2008), and then regulating the neuronal precursor niche of the 
hippocampus through phagocytosis  (Sierra et al., 2010, Sierra et al., 2015) Microglia even 
induce apoptosis of developing Purkinje cells of the cerebellum via production of 
superoxide ions (Marın-Teva et al., 2004).. In addition, microglia promote region and 
stage-specific neurogenesis, as observed in a study in which microglia supported the 
survival of layer V cortical neurons in postnatal mice through the production of 
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neurotrophic IGF-1 (Ueno et al., 2013). Besides undertaking roles in brain patterning, 
neurogenesis, and neuronal apoptosis, microglial cells shape the synaptic architecture of 
the brain through a dynamic spatial, and temporal contact with synapses, inducing postnatal 
synaptic pruning via a C3/CR3 complement-dependent mechanism and the 
CX3CR1/fractalkine signalling pathways (Paolicelli et al., 2011, Schafer et al., 2012, 
Kettenmann et al., 2013, Schafer et al., 2013, Zhan et al., 2014).  
The compounding evidence of the intricate role microglia plays in brain development also 
highlights the possibility of microglial dysfunction as a underlying mechanism for several 
neurodevelopmental and psychiatric disorders (Bilimoria and Stevens, 2015). Thus, it is 
crucial to understand the characteristics and genetic milieu of amoeboid microglia and the 
range of functions them might be involved in to ensure proper brain development.  
 
Figure 1-1 Amoeboid microglia imaged from the corpus callosum of a 5-day old rat 
brain.  
Microglia marker CD11b (red, white arrows) and DAPI (blue) stain nuclei. 
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1.1.2.2 Adult brain  
Emerging studies link microglia in the adult brain to surveillance and maintenance of the 
brain parenchyma (Nimmerjahn et al., 2005). Microglia assist in ‘fine tuning’ neuronal 
circuits and form an essential part of a quad-partite synapse with neurons alongside 
astroglia (Schafer et al., 2013, Nimmerjahn et al., 2005). Microglia from the developing 
brain mature alongside neurons and integrate into the brain tissue as a ‘ramified’ phenotype 
(Figure 1-2). Transcriptomic analysis of different stages of microglial development 
revealed transcription factor MAFB to specifically induce immunosuppression in the adult 
microglial phenotype, and enabling functions such as synaptic pruning, and neuronal 
maintenance which are attributed to adult microglial behaviour (Matcovitch-Natan et al., 
2016). 
Ramified microglia have characteristic dynamic processes which constantly probe brain 
microenvironment and interact with neurons (Nimmerjahn et al., 2005). Specifically, 
microglia interact with pre-synaptic boutons and post-synaptic spines of neurons, alongside 
peri-synaptic astrocytes at the synaptic cleft (Wake et al., 2009, Tremblay et al., 2010). In 
a pathological scenario, these interactions between microglia and the synapse lead to the 
synaptic stripping of contacted terminals (Wake et al., 2009).  
The mechanism of microglia interacting with synapses has been broadly attributed to the 
contributing effect of two neuronal signals, namely- “find me” and eat me”(Miyamoto et 
al., 2015). Studies so far compare neuronal cues to microglia to be a “find me” signal which 
can positively regulate microglial process motility and contact frequency (Nimmerjahn et 
al., 2005, Wake et al., 2009, Tremblay et al., 2010). After the “find me” signal, a “eat me” 
signal from synapses and neurites leads to their phagocytosis by microglia. Recent studies 
have implicated the C1q and C3 immune complement molecules in neurons which are 
11 
recognised by the receptor CR3 (CD11b/Cd18) in microglia to induce microglia-mediated 
phagocytosis (Miyamoto et al., 2015) . 
The past decade has seen a surge of studies investigating microglial function in the healthy 
brain. The close participation of microglia at the synapses point to their potential role in 
regulating synaptic plasticity and remodelling of neuronal circuits in health and as a 
potential contributing factor to dysregulation of neuronal plasticity during disease 
(Miyamoto et al., 2015).  
 
 
Figure 1-2 Ramified microglia imaged from the corpus callosum of a 28-day old rat 
brain.  




1.1.2.3 Aging brain 
Microglia ensure the proper functioning of the brain during adulthood, but what happens 
to microglial function in an aged brain? There is emerging evidence that microglia can 
undergo changes in morphology, function and cell number as the brain ages (Harry, 2013). 
Some changes include an increase in cell volume, shortening of processes, a decrease in 
process motility, and a change in distribution across brain regions (Hefendehl et al., 2014). 
Similar findings are observed in the microglia from an aged retina where, after the 
application of Adenosine Tri-Phosphate (ATP), an activating stimuli, microglia in young 
brains respond with an increase in process length and number, in contrast to microglia in 
aged brains which show process reduction (Damani et al., 2011). Most importantly, 
microglia in the aging brain show a slow and chronic post-injury response when compared 
to microglia in younger brains (Damani et al., 2011, Hefendehl et al., 2014, Lourbopoulos 
et al., 2015). Further, microglia in the aged brain exhibit reduced phagocytic abilities 
towards neuronal proteins like endogenous Aβ fibrils (Floden and Combs, 2011, Harry, 
2013) and a decrease in expression of genes related to phagocytosis and/or endocytosis 
(Orre et al., 2014), indicating a potential deficit in microglial functions. Microglial numbers 
are even seen to decrease in the aged brain (Lourbopoulos et al., 2015), concomitant with 
telomere shortening and decreased telomerase activity indicating aging and senescence of 
microglial cells (Flanary et al., 2007). 
Microglia in the aged brain also acquire a resistance to regulatory mediators such as 
transforming growth factor beta 1 (TGFβ1) and colony stimulating factor 1 (CSF1) 
(Rozovsky et al., 1998) Some implicate this behaviour to “microglial priming” where 
inflammatory stimuli in the microenvironment can prime microglia to systemic 
inflammation, and a secondary exposure can lead to an exaggerated microglial immune 
response leading to exacerbated neurodegeneration (Perry and Holmes, 2014). In 
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summary, microglia can undergo diverse age related changes in the aging brain. The age 
related deficit in microglial functioning could be causal to the chronic inflammation and 
neurological deficits that are hallmarks to aging related neurodegenerative diseases.  
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 Microglial activation in neuropathological conditions  
Microglial cells are macrophages of the brain which are involved in the maintenance of 
neuronal function and plasticity (Kettenmann et al., 2013). Before the newly described 
synaptic functions of microglia were discovered, microglial cells were known for their 
immune specific role in the brain. As the sole cell with immune capabilities in the brain, 
microglial cells contribute to the protection of the brain and its cellular components during 
any infection or injury (Chen and Trapp, 2016).  
Microglial cells are seen to contain receptor families, ion channels, neurotransmitters, 
neuro-hormones and neuromodulators, cytokines and chemokines, pattern recognition 
receptors and complement receptors to name a few (reviewed in (Kettenmann et al., 2011). 
During brain homeostasis, microglial cells are kept in a passive state via continued 
inhibitory signalling from healthy neurons through CD200, CD47, CD22, CD172, 
CX3CL1 and/or TREM2 (Hellwig et al., 2013). However, upon a disturbance to 
homeostasis, there is a decrease in inhibitory signals and an upregulation of several 
neuronal molecules that trigger microglial activation (Hellwig et al., 2013). Indeed, dying 
neurons in neuropathologies release different signalling molecules such as ATP, nucleic 
acids, mannose residues proteolytic enzymes, hyaluronic acid and fibronectin from 
degraded extracellular matrix. These signalling molecules altogether known as danger 
associated molecular patterns (DAMPs) (Weinstein et al., 2010, Block et al., 2007), are 
recognized by pattern recognition receptors (PRRs) on microglia and can trigger microglial 
activation (Kaminska et al., 2016, Kigerl et al., 2014, Magnus et al., 2012).  
In response to a pathological stimulus, microglial cells undergo a rapid morphological and 
functional change from the “ramified” phenotype towards an “activated” phenotype, with 
shorter processes (Figure 1-3) and added proliferative and migratory capabilities 
(Kettenmann et al., 2011, Dheen et al., 2007). Regulated, acute microglial activation allows 
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microglia to phagocytose cell debris and invading agents, regain tissue homeostasis and 
secrete neurotrophic factors such as BDNF (Batchelor et al., 1999), GDNF (Lu et al., 2005) 
and IGF-1 (Thored et al., 2009) to promote neural growth and repair (Chen and Trapp, 
2016). However, in many neuropathologies, including Alzheimer’s disease, Parkinson’s 
disease, Prion disease and ischemic stroke, a chronic activation of microglia is observed. 
The chronically activated microglia have been shown to  perpetuate inflammation by an 
excessive secretion of pro-inflammatory mediators, antigen presentation and the 
recruitment of peripheral immune cells (Block et al., 2007). The inflammatory response 
observed in these pathological scenarios leads to further neuronal death, which in turn 
activates more microglia in the vicinity. Thus, the entire system is caught in a cycle of self-
propagating microglia-mediated neurotoxicity which exacerbates neurodegeneration 
(Block et al., 2007). 
 Phenotypic diversity of activated microglia 
Activated microglia express a rich molecular repertoire which allow them to elicit a 
spectrum of responses ranging from pro-inflammatory to anti-inflammatory, dictated by 
the trigger, the environmental context and severity of the disturbance (Hanisch and 
Kettenmann, 2007, Hu et al., 2015). Activated microglia show functional phenotypic 
diversity in response to the damage stimuli (Hu et al., 2015, Dheen et al., 2007). They 
display similarities to macrophage phenotypes such as M1 (pro-inflammatory) and M2 
(anti-inflammatory). M1, pro-inflammatory microglia are believed to be classically 
activated, mimicking the in-vitro stimuli of lipopolysaccharide (LPS), a bacterial 
endotoxin, or IFNγ activated Toll like Receptor 4 (TLR4) signalling. The M2 phenotype, 
on the other hand, is alternately activated and can be further subdivided into the following, 
based on the polarizing signal: M2a (IL-4, IL-13), M2b (immune complexes, IL1β or LPS) 
and M2c (IL10, TGFβ or glucocorticoids), which are all associated with neuroprotective 
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and immunomodulatory programs (David and Kroner, 2011). In in vivo conditions, the 
phenotypes are temporally, spatially and functionally regulated based on the stage of 





Figure 1-3 Ramified and activated microglia imaged from the contralateral vs 
ipsilateral hemisphere respectively in the adult mouse hippocampus of a 24I/R MCAO 
ischemic brain. 
CD11b marks microglia in red indicated by white arrows from contralateral and ipsilateral 
hemispheres of a 24I/R MCAO mouse brain respectively, DAPI (blue) marks nuclei   
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 Molecular basis of phenotypic diversity of activated microglia 
Transcriptomic studies performed on microglia differentiate them functionally from 
peripheral macrophages and point to their signal specific transcriptional program and 
phenotypic plasticity (Beutner et al., 2013, Butovsky et al., 2014, Hickman et al., 2013, 
Freilich et al., 2013). The microglial immune response is stimuli dependent and mediated 
by various signalling pathways through effectors such as cell surface receptors, signal 
transducers and transcription factors (Nayak et al., 2014, Ransohoff and Perry, 2009, 
Dheen et al., 2007). Microglial activation in response to LPS is demonstrated to be 
physiologically comparable to microglial activation in neuropathologies (Zawadzka et al., 
2012). TLR-NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) 
signalling and JAK/STAT1 (Janus activated kinase/ Signal transducer and activator of 
transcription 1) signalling are the most predominant signalling pathways induced in LPS 
activated microglia (Zawadzka et al., 2012, Kaminska et al., 2016). TLR signalling has 
been shown to be activated in microglia in response to neuropathologies like intracerebral 
ischemia and haemorrhage, traumatic brain injury, hippocampal excitotoxicity and nerve 
transection injury (Kaminska et al., 2016, Ginhoux et al., 2013). Mice with TLR-4 
deficiency display protection against ischemia, along with a significant reduction of infarct 
size in the transient middle cerebral artery occlusion (MCAO) model, indicating TLR4 
mediated signalling to be a crucial aspect of ischemia pathology (Kilic et al., 2008, 
Ginhoux et al., 2013, Hyakkoku et al., 2010). Moreover, CD11b+ cells expressing TLR4 
were reduced in number in the ischemic striatum in TLR4-KO mice, indicating that TLR4 
is involved in microglial functions during neuropathology (Hyakkoku et al., 2010). 
The most common ligand used for TLR induction, specifically TLR4, is LPS. By 
consolidating signalling pathways during microglial activation and analysing 
overrepresented transcription factor motifs on co-regulated genes, transcription factors NF-
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κB, AP-1 (Activator protein-1), IRFs (Interferon regulatory factors), and STATs are found 
to play a central role in mediating classic microglial activation (Das et al., 2015). 
Illustration 1-2 depicts the key signalling mediators in TLR4-JAK/STAT signalling in 
microglia. An inflammatory trigger by LPS at the TLR4 receptor can initiate a cascade of 
signal transduction in microglia leading to innate and adaptive immune response (Yao et 
al., 2013, Pålsson‐McDermott and O'Neill, 2004, Kawai and Akira, 2011, Song et al., 
2011).  
 NF-κB, AP-1, IRFs induction through TLR signalling 
TLR signalling mediates the primary innate immune response in activated microglia (Jack 
et al., 2005). LPS, binds to TLR4, dimerising it and initiating the recruitment of adapter 
proteins (Kawai and Akira, 2011).The activation of TNF receptor associated factor 6 
(TRAF6) and Transforming growth factor beta-activated kinase 1 (TAK1) is the common 
factor in the subsequent induction of the AP1 and the NFκB pathways.  
The apoptosis signal regulating kinase (ASK1) is a member of the MAPKKK (Mitogen-
activating protein kinase kinase kinase) family and phosphorylates the c-jun N-terminal 
Kinase (JNK) collaborating in the induction of the AP1 transcription factor (cFos and 
cJun). The c-Jun N-terminal kinases (JNK)/MAPK pathway is responsible for the induction 
of several genes including cytokines, growth factors, and genes involved in cell 
proliferation, survival and stress response (Shaulian and Karin, 2002). The MAPK pathway 
has been implicated in the production of pro-inflammatory Interleukin 1β (IL-1β) in 
activated microglia (Kim et al., 2004).  
Subsequently, TAK1 activates an inhibitory complex consisting of inhibitory κB kinase 
alpha (IKKα), IKKβ and a scaffolding protein IKKγ (NEMO) that phosphorylate IκB for 
further ubiquitination and proteosomal degradation, setting NFκB free to translocate to the 
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nucleus and activate the transcription of several pro-inflammatory genes (Pålsson‐
McDermott and O'Neill, 2004). Alternatively, the TLR4 signalling can induce the 
expression of interferon response (IFN) genes. Interferons are central mediators of 
inflammation, immune response against viruses and even immune surveillance (Khorooshi 
and Owens, 2010). IFN-β generated this way can lead to the autocrine induction of the IFN 
signalling and the activation of the JAK/STAT pathway as a secondary response, which 
induces MHC antigen presentation, STAT1, and IRF members (Illustration 1-2, b) 
(Pålsson‐McDermott and O'Neill, 2004). Alternatively, the TLR4 induced production of 
IL6 can activate IL6 signalling and the further expression of IFN inducible genes 
(Illustration 1-2, c).  
 STAT induction through JAK/STAT signalling  
The JAK-STAT pathway centrally regulates an extensive range of Interferons (IFNs) and 
cytokine signalling (Shuai and Liu, 2003). The STAT family of transcription factors 
(STAT1, 2, 3, 4, 5a, 5b, 6) can be elicited by over 40 cytokines and growth factors towards 
a pro- or anti-inflammatory response. Upon a trigger on a receptor associated with JAK, 
STATs dock to the receptor and get phosphorylated (705 tyrosine) by JAKs, undergo 
dimerization (homo or hetero) and subsequently translocate to the nucleus to induce 
transcription of cell type specific genes. STATs have the ability to associate with one 
another in multiple combinations, giving them a wide range of targets (Rawlings et al., 
2004). STATs are thus, direct mediators between a receptor and genes downstream of the 
signalling pathway with a genomic binding signature unique to every cell type (Darnell, 
1997, Kang et al., 2013). A recent study revealed that novel genomic targets of 
transcription factors STAT 1 and STAT 3 in microglia play an important role in driving 
the microglial immune response (Przanowski et al., 2014). Overexpression of STAT1 and 
STAT3 together, induced a LPS-like inflammatory response, in microglia. Furthermore, it 
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was confirmed that the phosphorylation of STAT1 and STAT3 occurred as a secondary 
event, induced as a result of the LPS mediated TLR response (Przanowski et al., 2014).  
Besides the pro-inflammatory role of STATs, an IL10 driven anti-inflammatory signal 
using STAT3 as a mediator has also been demonstrated in microglial cells (Strle et al., 
2002). The IL10/STAT3 signalling axis induces repressors of inflammation, also termed 
anti-inflammatory response (AIRs) genes which suppresses the TLR4 and IL6 mediated 
pro-inflammatory signals (Hutchins et al., 2013) (Illustration 1-2, d, e). Indeed, SOCS1, 
a gene induced by STAT3 in response to IL10 signalling (Hutchins et al., 2012), targets 
key players of the pro-inflammatory TLR4 cascade, namely MAL, ASK1, and p65 and 
JAK1, 2 of the JAK/STAT signalling pathway (Yoshimura et al., 2007) (Illustration 1-2, 
e) .  
Transcriptionally relevant pSTAT3 targets, induced by an IL10 stimuli, were investigated 
by ChIP-seq (against pSTAT3 binding), and compared to RNA-seq of macrophages to 
identify the potential AIRs (Hutchins et al., 2012). Among the pSTAT3 targets induced by 
IL10 revealed by this dataset, genes Socs1, MafB, Il4ra, Fcrlb, and Itpr1 have been 
considered in the present study. Suppressor of cytokine signalling-1 (Socs1) is an avid 
suppressor of STAT1 activation and disrupts CD40 gene expression (Qin et al., 2006) 
among its other routes of negative pro-inflammatory regulation. V-Maf Avian 
Musculoaponeurotic Fibrosarcoma Oncogene Homolog B (MafB) supresses microglial 
proliferation and regulates cytoskeletal remodelling via activation of RhoA (Koshida et al., 
2015). Interleukin-4 receptor (Il4ra) mediates Il4 and Il13 signalling, which suppress NF-
κB signalling, thus polarizing microglia to the anti-inflammatory M2 phenotype. Fc 
Receptor-Like B (Fcrlb) belongs to the Fc receptor family which regulates phagocytosis 
in cells (Zhang et al., 2010). The Inositol 1,4,5-Trisphosphate Receptor, Type 1 (Itpr1) 
gene is upregulated in various neurological disorders including stroke. Furthermore, it is 
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involved in calcium signalling and the induction of apoptosis pathways (Yang et al., 2014, 
Tseveleki et al., 2010). 
Upon an insult to the CNS, signal transducers like STAT1, STAT3 interact with epigenetic 
moieties to induce chromatin regulation and the transcriptional activation of several gene 
sets involved in eliciting an immune response (Christova et al., 2007). The STAT family 
is vital to the microglial immune response through diverse mechanisms, yet no study has 
attempted to understand the epigenetic regulation of STATs in microglia and their role in 
the induction of pro- and anti-inflammatory phenotypes of microglia. Moreover, an 
understanding of epigenetic factors which regulate microglial activation through the 




Illustration 1-2 Schematic diagram of TLR4 and JAK/STAT signalling pathways in 
play in LPS activated microglia.  
  
a) Bacterial endotoxin lipopolysaccharide (LPS) can induce signaling from the TLR4 receptor with the 
activation and nuclear translocation of transcription factors AP1 and NFκB, which can induce transcription of 
a range of pro-inflammatory cytokines, and chemokines. Alternatively, TLR4 signalling leads to the induction 
of Type-I interferons (IFN) - IFN-β and IL-6 which can induce IFN signaling through the IFNAR (b) or IL-6R 
(c) respectively. This leads to the JAK-mediated activation of transcription factor family STATs, which can 
form homo and hetero-dimers and elicit a secondary inflammatory response. (d) In parallel, the induction of 
the IL-10 receptor activates STAT3 which can elicit an anti-inflammatory response (AIRs), which includes 
SOCS1, to suppress the production and activity of several pro-inflammatory factors (e) Adapted from 
Yoshimura et al. (2007) and Noppert et al. (2007). 
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 Epigenetics 
 Epigenetic regulation of an immune response 
A robust immune response requires a variety of proteins, including cytokines, chemokines, 
transcription factors, effector proteins, signalling molecules and possibly regulators of cell 
survival, proliferation, and motility (Lim et al., 2010). An added layer of complexity is the 
ability of cells to elicit a cell type- and stimuli- specific immune response (Smale, 2012). 
The specificity of the immune response is mediated by the ability of different receptors and 
sensors to induce diverse pathways and transcription factors that will eventually determine 
the transcriptional response of the cell (Akira et al., 2006). Epigenetic mechanisms are vital 
to such a cell-specific, stimuli-selective immune response. 
DNA in the cell is packaged into the small volume of the nucleus with the help of histone 
proteins, forming chromatin (Schuebel et al., 2016). Epigenetic mechanisms modulate the 
packaging of chromatin, and thus, its accessibility to regulatory elements, in order to elicit 
a lineage specific transcriptional program. The key players in enforcing epigenetic 
regulation are histone modifications, histone modifiers, and chromatin remodelers, which 
act in concert with signalling moieties and transcription factors to elicit epigenetic and 
transcriptional control (Liu et al., 2015, Zaret and Carroll, 2011). The focus of the present 
study is on histone modifications and their regulatory proteins.  
Histone modifications or histone marks are post-translational modifications at the N- and 
C- terminal regions of histone proteins that regulate the affinity of binding between DNA 
and the histone complex (Bannister and Kouzarides, 2011). The most well studied of them 
are methylation and acetylation. The affinity of DNA-histone binding determines the 
accessibility of the genomic information in a specific region to other regulatory proteins. 
By alteration of histone modifications, the cell specifically delineates a transcriptional 
program to suit its function and modulate its response to the environment (Bannister and 
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Kouzarides, 2011). The term “histone code” was initially coined to address the 
combinatorial language of histone marks which determine the transcriptional and 
functional state of a genomic region (Jenuwein and Allis, 2001). Histone modifications are 
regulated by proteins that are classified as readers – those which can access and recognize 
the histone mark, writers – those which can make the post-translational modification and 
erasers – those which can remove the post-translational modification (Chi et al., 2010) 
(Illustration 1-3). For example, lysine acetylation is carried out by histone 
acetyltransferases (HATs) as writers, proteins such as DPF3b-PHD12 that are able to 
recognize acetylated lysines, function as readers to recruit regulatory factors and chromatin 
remodelers to the genomic sites (Zeng et al., 2010), and finally, histone deacetylases 
(HDACs) which remove the modification off the lysine are erasers. The interplay between 
the ever growing list of histone marks and their regulatory proteins contributes to the 
labyrinth of complexity of the “histone code"’. With the advent of high-throughput 
techniques such as the ChIP-sequencing, the intricacy of the histone code has just begun to 
unravel and its fundamental importance in the pathophysiology of disease progression is 
being increasingly appreciated. 
 
 
Illustration 1-3 Epigenetic modifiers can either be writers (a), readers (b) or erasers (c).  
The balance of epigenetic regulators maintains the transcriptional state of the genome. Any 
dysregulation of the balance can have far reaching effects on chromatin organization and the 
epigenome of the cell. Figure adapted from Falkenberg and Johnstone (2014).  
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 H3K9ac and its epigenetic regulators (HDACs and HATs) 
Histone 3, lysine 9, acetylation (H3K9ac) is a histone mark specifically found to be 
enriched at the promoters of active genes in the cell (Kratz et al., 2010) (Illustration 1-4). 
The genomic distribution of H3K9ac is highly specific to cell type and can give information 
on the transcriptional and proteomic capabilities of the cell. More so, the enrichment of 
H3K9ac at a gene promoter gives a good representation of the accessibility of the gene 
promoter. (Chai et al., 2013). H3K9ac is maintained by the opposing crosstalk between 
two families of enzymes called Histone acetyltransferases (HATs) and Histone de-
acetyltransferases (HDACs). The HATs use acetyl CoA to transfer an acetyl group to the 
ε-amino group of the side chain of lysine, thus neutralising lysine’s positive charge and 
weakening binding of the histone to DNA, and increasing DNA accessibility (Bannister 
and Kouzarides, 2011).  
Conversely, HDACs reverse lysine acetylation on target proteins which include, but are 
not limited to histones. HDACs include the classical HDAC family and the Sirtuins family 
(Class III HDACs) with different structural homologies (Delcuve et al., 2012). The 
classical HDAC families were differentiated into classes, namely, Class I (HDAC I, 2, 3 
and 8), Class IIa (HDAC 4, 5, 7, 9), Class IIb (HDAC 6, 10) and Class IV (HDAC 11), 
along with the Sirtuins family namely Class III ( SIRT 1-7) (Seto and Yoshida, 2014). The 
HDACs were numbered in the chronological order of their discovery and subsequently put 
into classes based on their sequence, functional and structural homology (Seto and 
Yoshida, 2014). Class I members participate in corepressor complexes along with 
transcription factors to regulate transcription. They can have a gene specific role of either 
repressing or activating transcription (Nusinzon and Horvath, 2005) but are pre-dominantly 
transcriptional repressors. Class I HDACs are mostly localised in the nucleus and 
ubiquitously expressed, with an exception of HDAC3 whose expression is  tissue specific 
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(Seto and Yoshida, 2014). Class II enzymes have a cytoplasmic role. Class III HDACs -
Sirtuins require the NAD+ co-factor for their activity, whereas class IV represent Zn2+ 
dependent amidohydrolases.  
 
 
Illustration 1-4 Representation of H3K9ac enrichment distribution around the 




HATs and HDACs work in unison to balance the acetylation state of a genomic region 
dependent on the requirement of the cell (Yang and Seto, 2007). HATs and HDACs carry 
out transcriptional regulation as a part of large multiprotein complexes, containing co-
factors that can determine target specificity and cell-type specific role (Seto and Yoshida, 
2014, Jepsen and Rosenfeld, 2002). Early studies have shown that HDAC1 and HDAC2 
associate together with at-least three distinct complexes, namely Sin3, NuRD and CoREST 
(Ayer, 1999). Sin3 and NuRD complexes have a common core of four proteins: HDAC1, 
HDAC2, RbAp46, and RbAp48. Each complex is further supplemented by unique factors 
such as Sin3, SAP18 and SAP30 in the Sin3 complex, and Mi2, MTA-2 and MBD3 in the 
NuRD complex. The association of these unique factors with HDACs is indispensable to 
the formation of an enzymatically active complex (Seto and Yoshida, 2014). Similarly, 
HDAC1 and HDAC2 have been seen to associate with factors p110, p80 Sox-like and Co-
REST to form the Co-REST complex (Jepsen and Rosenfeld, 2002). HDAC3 requires the 
association of GPS2, TBL1 and NCoR/SMRT cofactors for maximal enzymatic activity of 
the HDAC3 (Wen et al., 2000). HDACs are thus regulated by their association to varying 
cofactors which switch their target specificity and fine tune their response to be specific to 
cell type (Illustration 1-5). 
Even though the gene specificity of HDAC complexes has not been extensively explored 
in microglia, a study showed the recruitment of the co-repressor coREST complex 
including HDAC1 by the Nuclear receptor related 1 (NURR1) protein to induce a 
transcriptional repression of pro-inflammatory gene promoter Nos2 regulated by the NF-
κB-p65 protein (Saijo et al., 2009), demonstrating the repressive effects of HDAC 
complexes in microglia.  
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Illustration 1-5 Dynamics of HDAC complexes and their target specificity 
a) Individual HDAC proteins are observed to have compromised catalytic activity. They need to 
associate with other co-factors as parts of large multiprotein complexes to trigger their enzymatic 
activity. (b) HDAC1, HDAC2 associated with RbAP46 and RbAP48, switch from co-factors Mi2, 
MBD3, MTA2 to Sin3, Sap30, Sap18 to form complexes NuRD and Sin3 respectively. HDAC1 and 
HDAC2 can also form complex Co-REST in association with factors p110, p80, co-REST and Sox-
like. (c) Different HDAC complexes exhibit different genomic targets. (d) A dynamic crosstalk 
between HDACs and HATs (eg. GCN5/pCAF, Tip60) maintains H3K9ac levels in the cell. Adapted 
from Delcuve et al. (2012). 
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 HDAC inhibitors 
Neurodegeneration has been associated with decreased HAT activity, and a loss in global 
acetylation levels (Saha and Pahan, 2006, Rouaux et al., 2003). Subsequently, 
investigations carried out in the use of HDAC inhibitors to treat neurodegeneration, found 
them to be therapeutically beneficial in various neuropathologies such as multiple sclerosis 
(Camelo et al., 2005, Ge et al., 2013), Alzheimer’s disease (Qing et al., 2008, Kilgore et 
al., 2010, Sung et al., 2013), Huntington’s disease (Hockly et al., 2003, Thomas et al., 
2008), in ischemic stroke (Faraco et al., 2006, Kim et al., 2007, Ren et al., 2004, Xuan et 
al., 2012, Yildirim et al., 2008) and traumatic brain injury (Dash et al., 2010, Na'ama et al., 
2009, Wang et al., 2013).  
Investigation of epigenetic regulation in microglia have so far been dominated by a series 
of studies on HDACs and the effect of HDAC inhibitors on microglial functions. In an 
attempt to elucidate the effects of HDAC inhibitors in microglia, many groups have 
characterised microglial behaviour using a variety of HDAC inhibitors including broad 
spectrum inhibitors such as Sodium butyrate, TSA, SAHA or HDAC specific inhibitors 
such as MS-275 (Kaminska et al., 2016). A comparative analysis of studies in the effects 
of HDAC inhibitors on microglial activation is depicted in Table 1-1.  
Several studies support observations that HDAC inhibitors suppress pro-inflammation and 
support anti-inflammatory signalling pathways in microglial cell lines and primary 
microglia (Table 1-1). In contrast, some groups have reported that HDAC inhibitors induce 
a pro-inflammatory effect in microglia, and it has been suggested that variations in results 
depend on the experimental setup and treatment schedule (Kaminska et al., 2016).  
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There is currently debate in the field about HDAC inhibitors supressing microglial pro-
inflammatory behaviour. The present study aims to resolve this by leading an in vivo 
investigation on the effect of HDAC inhibition in microglia activated in ischemic stroke. 
 Sodium butyrate 
In the present study, we used HDAC inhibitor sodium butyrate (SB) which is a sodium salt 
of butyric acid shown to have a therapeutic efficacy against several diseases including 
ischemic stroke (Langley et al., 2009, Kim et al., 2009). Treatment with SB resulted in a 
50% reduction in infarct volume 24h post ischemia in a rat model of permanent ischemia, 
an effect that was retained even 11 days post ischemic induction (Kim et al., 2007). Langley 
et al. (2008) similarly confirmed that SB could decrease infarct volume by more than 50% 
in a rat model of permanent ischemia seen after 24h post ischemia. Post-insult treatment of 
SB has been shown to induce neurogenesis in the rat model of permanent ischemia (Kim 
et al., 2009). In addition, several in vitro investigations demonstrate SB to elicit anti-
inflammatory behaviour in activated microglia (Table 1-1). Despite various accounts of SB 
suppressing the microglial inflammatory response, no investigation has yet validated the 
effect of HDAC inhibitors in microglia in vivo.  
SB inhibits most HDACs except HDAC Class III, and HDAC -6, and -10 of class II. HDAC 
class I and II depend on an essential Zn2+ ion that is responsible for the catalytic action of 
HDACs (Davie, 2003). However, SB is shown to be a non-competitive inhibitor of HDAC 
and does not bind to its active site (Cousens et al., 1979). The binding mechanism through 





 Table 1-1 Studies on effect of HDAC inhibition on the microglial inflammatory response 




Microglia cell type 
Treatment 
schedule with 
respect to LPS 
stimuli 
Concentration Effect observed Reference 
1 SB, TSA Rat primary microglia Pre-treatment 
SB:1.2 mM  
TSA: 50 nM  
Anti-inflammatory 
(Chen et al., 
2007) 
2 SB 
Rat primary microglia 
Hippocampal slice cultures 
Co-cultures (neurons, 
microglia, astrocytes) 
Pre-treatment SB: 2.5 mM Anti-inflammatory 
(Huuskonen et 
al., 2004) 
3 TSA, VA Human primary microglia Pre-treatment 
TSA: 400 ng/ml 
VA: 4 mM 





Mouse primary microglia Post-treatment 
Scriptaid: 1 μM 
SAHA: 2.5 µM 
VPA: 4 μM 
Anti-inflammatory 





Mixed glial cultures 
(astrocytes and microglia) 
Simultaneous 
treatment 
SAHA: 1 μM 
ITF2357: 1 μM 
Anti-inflammatory 





Primary rat microglia Pre-treatment 
TSA: 30 nM 
SAHA: 1 μM 
Anti-inflammatory 
(Kannan et al., 
2013) 

















(Suuronen et al., 
2003) 
9 TSA Murine N9 cell line 
Simultaneous 
treatment 
TSA: 20 nM Pro-inflammatory 






 Ischemic Stroke 
 Cerebrovasculature of the brain 
The cerebrovasculature is an intricately designed system which supports brain function. 
The human brain normally receives close to 700-750 ml of blood per min and has an 
enormous requirement for oxygen, glucose and other nutrients for its proper functioning 
(Siegel and Sapru, 2006). The cerebrovasculature is especially structured to support a 
continuous supply of blood to all parts of the brain towards its proper functioning.  
Blood supply to the brain is supported by two sets of major arteries, namely the internal 
carotid artery and the vertebral artery. The basilar artery supplies blood to the brainstem, 
cerebellum and the occipital lobe. These arteries and their branches exist in pairs that are 
symmetrically spread through either hemisphere of the brain and supply similar neuronal 
structures on either side (Illustration 1-6)(Siegel and Sapru, 2006).  
The internal carotid artery originates from the common carotid artery on either side at the 
level of superior border of the thyroid cartilage. Upon entering the cranial cavity through 
the carotid canal, the internal carotid artery forks into the ophthalmic artery, the posterior 
communicating artery, the anterior choroidal artery, the anterior cerebral artery and finally 
the middle cerebral artery (MCA). Each artery system supplies blood to spatially different 




Illustration 1-6 Arterial supply of the brain  
Blood supply to the brain derives from two major arteries, the internal carotid artery and the 
vertebral artery connected by the basilar artery. The internal carotid artery gives rise to the middle 
cerebral artery, along with the ophthalmic, posterior communicating, anterior choroidal and anterior 
cerebral arteries. The middle cerebral artery gives rise to the lenticulostriate arteries among others 
(subsequently described). The anterior cerebral artery along with the anterior communicating artery 
and Posterior communicating artery form a closed loop of blood circulation known as the Circle of 
Willis. Drawn with reference to Siegel and Sapru (2006) 
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Middle cerebral artery 
The emphasis in this study is the middle cerebral artery (MCA) (Illustration 1-7) which 
gives rise to 1) The lenticulostriate artery, supplying blood to the striatum consisting of the 
putamen, caudate nucleus and the anterior limb of the internal capsule encompassing the 
basal ganglia and the motivation and reward perception centre of the brain. 2) The 
orbitofrontal artery and 3) The precentral (Pre-Rolandic) and central (Rolandic) branches 
supplying blood to different regions of the frontal lobe in charge of executive function and 
motor functions. 4) The anterior and posterior parietal arteries which supply the parietal 
lobe where control of sensory functions resides. 5) the angular artery supplying blood to 
the angular gyrus in the parietal lobe which controls language processing, and spatial 
cognition among other functions, and lastly 6) The anterior, middle and posterior temporal 
arteries supplying blood to different regions of the temporal lobe and the lateral portions 





Illustration 1-7 Middle cerebral artery and its branches  
The middle cerebral artery arising from the internal carotid artery supplies blood to the striatum 
through the lenticulostriate arteries. It further supplies blood to various regions in the lateral 
convexity of the cerebral hemispheres, including parts in the temporal lobe and occipital lobe 
through the temporal arteries, in the frontal lobe through the Orbitofrontal, Pre-central (Pre-rolandic) 
and Central (Rolandic) arteries, and the parietal lobe through the Parietal branches which consist of 




 Cerebral ischemia pathophysiology 
Stroke is a cerebrovascular disorder characterized by the blockage of blood vessels in the 
brain causing ischemia or their rupture leading to haemorrhage. Statistic on the incidence 
of stroke in Singapore indicate that stroke is the fourth leading cause of death, out of which 
75% strokes are ischemic (Oh, 2012, Venketasubramanian and Chen, 2008). Being the 
major cause of long-term physical disability in the world (Mackay et al., 2004), an 
increasing ageing population is expected to drastically rise the burden of stroke and post-
stroke rehabilitation in the near future.  
Ischemic stroke is usually caused by blockage of arteries in the brain due to atherosclerotic 
lesions or thrombosis (due to blood clots) in blood vessels supplying the brain. When blood 
supply to any of these arteries gets blocked, the loss of blood leads to metabolic stress and 
a complex cascade of biochemical and molecular changes that eventually lead to cerebral 
ischemia and death of neurons. The resulting injured brain tissue is called an infarct. The 
blockage of the Middle cerebral artery is the common cause of human ischemic stroke 
(Durukan and Tatlisumak, 2007) (Illustration 1-7). An occluded middle cerebral artery 
can elicit symptoms such as contralateral hemiplegia predominantly in the upper 
extremities of the body as the upper limb region is represented in the lateral position of the 
pre-central gyrus. A contralateral sensory loss might also be seen which includes the loss 
of ability to discriminate between stimuli of different intensities. Aphasia (speech deficit) 
might occur if the left hemisphere is involved (Siegel and Sapru, 2006).  
The societal burden of ischemic stroke is further exacerbated by the lack of drug treatments 
to prevent acute or long term damage. The current treatment for ischemic stroke, and the 
only FDA approved one (Armstead et al., 2010), involves the use of tissue plasminogen 
activator (tPA) to dissolve the blockage (blood clot) and ensue reperfusion of blood 
(Disorders and Group, 1995). However, it has shown inconsistent therapeutic efficacy, 
38 
even if it is administered in the 3h-4.5h therapeutic window given to rescue a stroke patient 
after onset of stroke (Anttila et al., 2016, Lansberg et al., 2009, Armstead et al., 2010). 
Studies on estimating the therapeutic efficacy of tPA found that recombinant tPA (rtPA) 
initiated complex hemodynamic changes leading to an initial hyperperfusion and a delayed 
hypoperfusion response causing increased ischemic injury in a dose dependent way (Kilic 
et al., 2001). Earlier reports of an increase in infarct size due to tPA treatment  were 
attributed to changes in perfusion, with secondary hypercoagulability seen to interfere with 
brain perfusion after rtPA delivery (Kilic et al., 2001).  
Besides the side effects of tPA treatment including edema, Blood Brain Barrier (BBB) 
permeability or haemorrhage (Adibhatla and Hatcher, 2008), the short therapeutic time 
window to rescue a stroke patient remains a resounding factor in the effective treatment of 
stroke, as a large cohort of stroke victims may not be diagnosed or be able to gain adequate 
care in such a short time. The severe lack of medical alternatives to treat ischemic stroke 
make it imperative to conduct further research into potential therapeutics, which might lend 
neuroprotection and lessen the chances for neurological deficit and disability.  
 Middle cerebral artery occlusion (MCAO) 
In order to mimic the closest therapeutic scenario of acute ischemic stroke in humans, 
scientific studies are conducted in rodent models of transient focal ischemic injury. The 
most common method is the middle cerebral artery occlusion. Transient middle cerebral 
artery occlusion is able to mimic the clinical scenario of reperfusion during the currently 
used tPA treatment to rescue a stroke patient (Liu and McCullough, 2011). 
The present study has been conducted in a transient middle cerebral artery occlusion 
(MCAO) model of focal ischemic stroke in mice, undergone ischemia induction by an 
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intraluminal suture method for 1h following perfusion for 24h after which animals were 
euthanized.   
 Microglial inflammation in ischemic stroke 
Neuroinflammation is one of the main pathophysiological contributors of ischemic stroke, 
which is mediated by microglia contributing to irreversible neuronal damage (Moskowitz 
et al., 2010, Tobin et al., 2014). Microglia are activated within minutes of ischemic stimuli 
(Kazuyuki and Shinichi, 2004).The inflammatory response to ischemic stroke is foremost 
mediated by microglia as the first responders, later joined by a temporal recruitment of 
peripheral immune cells (Lee et al., 2014, Gelderblom et al., 2009). A detailed evaluation 
of the temporal profile of immune cells spread at the lesion shows microglia to be present 
in majority up to day 1-2 of injury, with a small minority of peripheral macrophages, until 
neutrophil infiltration at day 2-7 post ischemia (Jin et al., 2010). Another hallmark of 
ischemic stroke is blood brain barrier permeability. Disruption of the BBB can lead to 
cerebral vasogenic edema, haemorrhage, and immune cell infiltration, exacerbating 
neurotoxicity (da Fonseca et al., 2014, Ma et al., 2016) Activated microglial cells play a 
critical role in BBB permeability as microglial cells exhibit an increase in MMP9 (matrix-
mettalloprotinase-1) expression and phagocytose endothelial cells, thus contributing to the 
compromised BBB integrity as observed in ischemic stroke (Ma et al., 2016, Jolivel et al., 
2015).  
In vivo imaging studies in humans after ischemia showed microglial cells to be mainly 
present in the infarct core, and extending to the peri-infarct over time (Tomimoto et al., 
1996, Krupinski et al., 1995). Clinical studies observed activated microglial to be present 
in the human brain at the acute phase (Tomimoto et al., 1996, Krupinski et al., 1995), the 
sub-acute phase (Price et al., 2006) and the recovery phase (Gulyás et al., 2012) during 
ischemic stroke. However, spatial differences in the localisation of activated microglia, 
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either in the infarct or peri-infarct associated differently with tract damage (Thiel et al., 
2010). Microglial activation, mainly present in the infarct had a negative clinical outcome, 
whereas microglial activation in the peri-infarct had a positive outcome (Thiel et al., 2010). 
A need has been recognized for evaluation of more patients to enable a longitudinal study 
on the spatial evolution of microglial activation in the ischemic brain, towards evaluating 
its dominant neuroprotective or neurotoxic role in disease progression (Thiel and Heiss, 
2011, Ma et al., 2016). 
The exact role of microglia during ischemic stroke and if their presence is beneficial or 
detrimental to disease progression is still unclear (Ma et al., 2016). On one hand microglia 
compromise BBB integrity and exert their pro-inflammatory immune response at the 
infarct, which can worsen neuronal death (da Fonseca et al., 2015, Jolivel et al., 2015). On 
the other hand, microglial activation mitigates neuronal apoptosis, mediates repair 
processes with the production of neurotrophic factors, and the subsequent clearance of 
cellular and tissue debris to assist in neurogenesis post ischemic stroke (Faustino et al., 
2011, Lalancette-Hébert et al., 2007, Nunan et al., 2014, Thored et al., 2009).  
While, more investigation needs to be done on microglial activation in a human brain in 
response to ischemic stroke, studies on animal models of ischemia have found compelling 
evidence of microglia showcasing variable phenotypes during disease progression 
(reviewed by Ma et al. (2016)), with microglial phenotypes varying spatially and 
temporally with respect to disease progression (Perego et al., 2011). More needs to be 
understood about the regulatory mechanisms in microglial activation that guide their 
response to the varying micro environmental stimuli during ischemia progression. More 
so, the ability to modulate microglial behaviour from neuroinflammatory towards 
neuroprotective will go a long way in addressing microglia-mediated neuroinflammation 
in the treatment of ischemic stroke.   
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 Motivation of the present study 
Recent developments in the understanding of microglial function are showing microglia to 
be far greater contributors to brain health than previously believed. Even with the boom in 
studies investigating microglial function, microglia activation and its phenotypic 
complexity in health and disease are still poorly understood. Microglial activation, if not 
fine-tuned to its sensitive environment, can become chronic in nature and cause excessive 
neuroinflammation negatively impacting disease outcomes as seen in ischemic stroke and 
other neuropathologies (Block et al., 2007). Nevertheless, it is important to note than 
microglial cells also have the arsenal for neuroprotection and are constant contributors in 
maintaining homeostasis and neuronal function in the brain parenchyma (Hellwig et al., 
2013). Harnessing the neuroprotective function of microglia while suppressing the 
neurotoxic behaviour is a potential therapeutic alternative to treat neuroinflammation in 
ischemic stroke, and thus, forms the basis of the present study.  
Additionally, to find a molecular basis of a phenotypic switch, it is imperative to 
understand the molecular mechanisms at play in microglial activation. Epigenetic 
processes in the cell are upstream mediators to nearly all genomic functions, ranging from 
lineage specification to response to environmental stimuli (Jaenisch and Bird, 2003). Over 
the last decade, dysregulation of epigenetic processes have been implicated in several 
diseases, including neuropathologies and brain disorders (Portela and Esteller, 2010, 
Dolinoy et al., 2007, Gräff and Mansuy, 2009, Matt and Johnson, 2016, Wes et al., 2016, 
Schuebel et al., 2016). Even though epigenetic mechanisms contribute greatly to the 
regulation of the immune response, the understanding of epigenetic regulation in microglia 
and its activation, especially chromatin based regulation is severely lacking. 
To address this gap in knowledge, this study leads an investigation into epigenetic 
regulation; in specific, into H3K9ac mediated regulation, that is crucial to the “gene 
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activation” process during the induction of an immune response, in activated microglia, 
towards therapeutic alteration of microglial behaviour in ischemic stroke. 
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HYPOTHESIS 
It is hypothesised that Histone modifications, in particular H3K9ac,  
determine the inflammatory response of microglia, by altering expression levels of pro-  
and anti-inflammatory genes in neuropathological conditions,  




AIMS OF THE STUDY 
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2 Aims of the study 
 Characterisation of H3K9ac expression in microglia in a healthy brain 
Microglial cells appear as ‘amoeboid’ in shape in early post-natal stages and transform 
into ‘ramified’ during their progression to adulthood (Rangarajan et al., 2012). It was 
aimed to characterize H3K9ac levels in microglia and to investigate potential changes 
during microglial maturation upon development into adulthood. (Results in Section 4.1) 
 Characterisation of H3K9ac expression in microglia under ischemic stroke 
conditions in mice 
Microglial activation involves a morphological and functional shift in microglial 
phenotype from the surveillant ramified state to an activated form. Ischemia stroke 
pathophysiology is concomitant with microglial activation (Gulyás et al., 2012). As the 
induction of an immune response elicits gene activation (Lim et al., 2010), an 
upregulation of H3K9ac might occur during microglial activation. Thus, we 
hypothesized that H3K9ac level is increased in activated microglia in the ischemic brain 
in a mouse model of middle cerebral artery occlusion. (Results in section 4.2, 4.3) 
 Evaluation of neuroprotection imparted by HDAC inhibition using sodium 
butyrate in ischemic mice 
Several studies have described the neuroprotective aspects of HDAC inhibition in 
cerebral ischemia (Kim et al., 2009, Langley et al., 2009). We hypothesized that 
neuroprotective feature of HDAC inhibition persists in 24I/R MCAO model upon 
treating with HDAC inhibitor SB. The main objectives of this part of the study were:  
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 Investigation of neuronal viability in transient MCAO after treatment with 
HDAC inhibitor, SB (Results in Section 4.5) 
 Investigation of phenotypic changes in activated microglia in ischemic mice 
treated with HDAC inhibitor, SB 
We hypothesized that the neuroprotective effect observed upon sodium butyrate 
treatment in ischemic mice was due to a suppression of microglial pro-
inflammatory phenotype. This hypothesis was addressed as follows: 
2.3.2.1 Determination of changes in H3K9ac levels in activated microglia 
in HDAC inhibitor treated ischemic mice (Results in Section 4.4) 
2.3.2.2 Determination of the change in expression of pro-inflammatory 
mediators in activated microglia in HDAC inhibitor treated 
ischemic mice (Results in Section 4.6, 4.7) 
2.3.2.3 Determination of the change in expression of anti-inflammatory 
mediators in HDAC inhibitor treated ischemic mice (Results in 
Section 4.8) 
 Investigation of the immediate effects of HDAC inhibition via sodium butyrate 
in activated microglia at the molecular level 
As the phenotypic alterations in microglia were observed in response to HDAC 
inhibition during ischemic stroke after 24 h of ischemic induction (18 h of SB 
treatment), we aimed to investigate the immediate molecular events following HDAC 
inhibition in vitro. We hypothesized that HDAC inhibition alters H3K9 acetylation 
genome wide bringing about changes in chromatin regulation and transcription, which 
alters the microglial activation phenotype. This hypothesis was addressed by 
investigating H3K9ac enrichment at gene promoters of anti-inflammatory and pro-
inflammatory genes. The objectives of this part of the study were: 
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 Determination of alterations in H3K9ac enrichment at specific gene promoters 
in microglia in response to HDAC inhibition (results in Section 4.9-4.11) 
 Determination of transcriptional changes in microglia in response to genomic 
alterations of H3K9ac upon sodium butyrate mediated HDAC inhibition 
We hypothesized that the genome wide alterations in H3K9ac enrichment induced 
by SB in activated microglia alter expression profiles of pro- and anti-
inflammatory genes. This hypothesis was addressed by: 
2.4.2.1 Determination of changes in expression levels of pro-inflammatory 
genes during HDAC inhibition (Results in Section 4.12, 4.13) 
2.4.2.2 Determination of changes in expression levels of anti-inflammatory 
genes during HDAC inhibition (Results in Section 4.14) 
 Delineation of the signalling pathway in activated microglia, that is elicited in 
response to sodium butyrate mediated HDAC inhibition (Results in Section 
4.15-4.17) 
 





3 Materials and Methods 
 Animals 
Animals (as listed in Table 3.1 below) were purchased from Invivos, Singapore. All animal 
handling procedures were carried out in accordance with the National University of 
Singapore Institutional Animal Care and Use Committee (IACUC) guidelines and were 
approved (NUS/IACUC/R15-0051). All efforts were made to minimize pain and number 
of animals used. The table shows the number of animals used in the experiments listed in 
this study. Number of animals used for trials have not been included here.  
  
Experiment Treatment group Species Age Number 




4 weeks 5 
LPS treatment 
LPS 




Artery Occlusion  
Sham 
Mouse +8 weeks 
6 
24I/R MCAO 8 
24I/R MCAO+SB 6 
Primary culture of 
Microglia 
 Rat 3 days 24 pups 
Table 3-1 Animals used in the study 
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 Drug treatment 
 Lipopolysaccharide (LPS) treatment 
Male wistar rats of ages 4 weeks old (male) were used for these studies (n=3). The LPS 
treated experimental group consisted of rats given an intraperitoneal (i.p) injection of the 
bacterial endotoxin lipopolysaccharide (LPS at 1 mg/ kg (Cat# L6529-1MG; Sigma-
Aldrich) with double doses (3hrs interval) and sacrificed after 6hrs post-treatment (n=3). 
Rats injected with equal volumes of saline served as controls.  
Cells (BV2 microglia) were treated with LPS at a concentration of 1 μg/mL for 1, 3 and 6h 
respectively to activate microglia. Cells were treated with LPS under serum-free 
Dulbecco's Modified Eagle's Medium (DMEM).  
 Sodium butyrate treatment 
For SB treatment towards middle cerebral artery occlusion, C57BL/6 mice (n=4) were 
administered 300 mg/kg SB (Cat# 303410, Sigma-Aldrich) or saline, intraperitoneally, 1hr 
before Ischemia/Reperfusion (I/R) (pre-treatment), and 6 h after initiation of reperfusion 
(post-treatment). Dosage parameters were determined in reference to earlier studies (Kim 
et al., 2007, Ferrante et al., 2003, Ilić et al., 2002)(Illustration 3-1). Sham consisted of 
animals where the arteries were visualized but not disturbed.  
In vitro, groups with HDAC inhibitor (HDACi) Sodium Butyrate (Cat# 303410, Sigma-
Aldrich) treatment consisted of BV2 cells pre-treated with SB (2.5 mM) overnight before 
LPS treatment the next day as in previously published protocols (Huuskonen et al., 2004). 
Primary microglia, due to their sensitive nature and susceptibility to stress-induced 
apoptosis were pre-treated with SB for 1h before the start of 6h LPS treatment.  
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Illustration 3-1 Schematic describing the timeline of SB treatment during MCAO  
 
 Middle cerebral artery occlusion (MCAO) 
 Principle 
The experimental middle cerebral artery occlusion (MCAO) animal model was developed 
to mimic the pathophysiology and other related complex events that occur during stroke 
and its progression in human. The intraluminal filament method of MCAO involves, first 
temporarily ligating appropriate blood vessels to prevent internal haemorrhage, and then 
inserting a filament through the internal carotid artery in the mouse brain, to block blood 
flow to the middle cerebral artery. After the induction of ischemia for an hour (transient 
MCAO), the blockage is removed and the vessels are sutured (reperfusion).  
 Procedure 
The MCAO surgery was carried out in collaboration with Associate Professor Thiruma V. 
Arumugam. C57BL/6NTac mice were bought from Invivos and maintained under 
pathogen-free conditions for in vivo experiments. All animal experiments were performed 
according to IACUC guidelines. All animal experiments were randomized and blind. 
Excessive bleeding or death within 24h of tMCAO was considered as exclusion criteria. 
Male mice (10-22 weeks old) were weighed and anesthetized using Isofluorane (mixed 
with oxygen) for focal ischemia-reperfusion (stroke). MCAO was performed using an 
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intraluminal filament method (6-0 nylon) (Illustration 3-2). A midline neck incision was 
made after which the left external carotid artery (ECA) and the left pterygopalatine artery 
were isolated and ligated. This was followed by clipping the internal carotid artery (ICA) 
at the peripheral site of the bifurcation of the ICA and the pterygopalatine artery. A blunted 
tip of the 6-0 nylon monofilament (0.2-0.22mm diameter) was advanced through the ICA 
towards the carotid bifurcation of the ICA and ECA. The nylon thread and ECA were 
ligated with 6-0 silk sutures, and the ECA was pierced and rotated with the nylon thread. 
The nylon thread was advanced until the nylon thread tip was >6mm and <9mm distance 
from the ICA–pterygopalatine artery bifurcation and the ICA-ECA bifurcation, 
respectively. The left middle cerebral artery was accessed through a craniotomy and a 0.5-
mm Doppler probe (Moor LAB, Moor Instruments, Devon, UK) was positioned 
approximately 1 mm posterior to the bregma and 1 mm lateral to the midline underlying 
the parietal cortex Animals were included in the study on the basis of successful MCA 
occlusion, displaying >=80% drop in cerebral blood flow tested through laser Doppler 
flowmetry. The animals were excluded if the vessel wall was perforated during the 
insertion of the thread as seen if sub-arachnoid blood is present at the time of sacrifice 
similar to previously published procedures (Lok et al., 2015). The nylon thread was 












Immunohistochemical analysis of tissue requires intact structures in tissues and cells, 
including cellular structures, proteins, and nucleic acids, to be preserved for analysis. This 
is achieved by treating the tissue with fixatives such as aldehydes and alcohols, which 
prevent cellular degradation and protein denaturation (Jamur and Oliver, 2010). 
Transcardial perfusion is used for circulating the fixative through the vasculature of the 
animal. It enables the usage of the animals’ circulatory system to replace blood with saline, 
and subsequently with fixative; and enables circulation to all body parts of the animal, 
including the brain (Paul et al., 2008).  
 Materials 
1. Paraformaldehyde (PF), Cat. No. P001, TAAB Laboratories, UK 
2. 0.1M sodium dihydrogen phosphate 
3. 0.1M disodium hydrogen phosphate 
4. Ketamine/Xylazine cocktail (0.2 ml/100 gm); MD2 vivarium 
 
 Procedure 
3.4.3.1 Preparation of Paraformaldehyde  
Required volume of 0.1M phosphate buffer was prepared by mixing 4 parts of 0.1M 
disodium hydrogen phosphate with 1 part of 0.1M sodium dihydrogen phosphate by 
constant stirring using a magnetic stirrer. The pH of the buffer was adjusted to 7.4. 20g of 
PF was added per 1000ml 0.1M freshly prepared phosphate buffer (pH 7.4) to make 2% 
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PF solution and was heated until completely dissolved. The solution was cooled and then 
filtered before further use.  
3.4.3.2 Transcardial perfusion 
Adult rats were restrained and anesthetized with a Ketamine/Xylazine cocktail (0.2 ml/100 
gm). Adult mice were euthanized using CO2. The anesthetized animal was laid on its back 
on a wax block, and the toe-pinch response was used to confirm if the animal was 
unresponsive and effectively anesthetized. Its fore and hind paws were pinned to the wax 
block. A scalpel was used to make an incision along the thoracic and abdominal midline. 
The skin with fur was parted, and the diaphragm was cut carefully. Next, the rib cage was 
cut taking care not to damage the heart and the lungs.  A winged perfusion needle (23-
gauge size), connected to two containers, filled with ringers’ solution and 2% PF 
respectively was flushed with Ringer’s solution to release any air bubbles. The needle 
dripping with ringers was inserted into the left ventricle of the heart, immediately followed 
by snipping the right auricle of the heart. Once, all the blood was flushed out of the animal 
and the liver looked pale, the ringer’s solution was switched with PF. The effectiveness of 
the perfusion was judged by observing muscle contractions throughout the animal’s body. 
PF was circulated until the animal was stiff. Following perfusion, an incision was made in 
the skull, and the brain was carefully isolated. Brains were stored in 2% PF, 4ºC overnight, 




Cryosectioning involves quick freezing the fixed tissue in an embedding matrix for the 
purpose of sectioning it at a pre-determined thickness for the purpose of immune-
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histochemical analysis. Gelatin coating of glass slides enables the sticking of the tissue to 
the glass slide, and also ensures it remains attached throughout the downstream process.  
 Materials and Equipment 





1.04080 (Merck, Germany) 
2.  Chrome alum 
(Chromium(III) 
potassium sulfate 
1.01036 (Merck, Germany) 
3.  Distilled water: 600 
ml 
  
4.  Cryostat Leica CM 3050 S Leica Instruments 
GmbH, Germany 
5.  Shandon M-1 
Embedding Matrix 
Cat. No. 1310 Thermo Scientific, 
MA, USA 
6.  Glass slides   
 
 Procedure 
3.5.3.1 Gelatin coating of slides 
A gelatin solution was first prepared by dissolving 9 g gelatin in 600 ml of water by heating 
with constant stirring. The solution was left to cool after which 0.9 g of chrome alum was 
added and mixed. The resulting solution was filtered using a Whatman’s filter paper. 
Meanwhile, glass slides were washed in absolute ethanol and left to dry completely in a 
fume hood. The clean glass slides were then immersed in the gelatin solution for 1 min and 
left to dry overnight. Gelatin coated slides were stored in an oven. 
3.5.3.2 Cryosectioning brain tissue 
Following the dehydration of fixed brain tissue in sucrose, the specimen was trimmed – 
and cerebrum was isolated.  A small amount of embedding matrix was applied to a metal 
chuck and was immersed in liquid nitrogen until a thin layer of the frozen matrix was 
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observable on the chuck. The cerebrum was carefully mounted on the frozen matrix. The 
rest of the specimen was covered with matrix and immersed in liquid nitrogen rapidly. The 
metal chuck was mounted inside the cryostat maintained at a temperature of -15 ºC and 
with an object temperature of -10 ºC. Coronal sections of the cerebrum were collected at a 
thickness of 20 µm and mounted on gelatin slides. Mounted slides were dried overnight at 
room temperature (RT) and stored at -80 ºC for further immunofluorescence experiments.   
 Primary microglial culture 
 Principle 
Brain tissue isolated from post-natal rat pups are grown in glial selection medium to enrich 
glial cells, from which pure microglial population was collected through the shaking 
method. The principle of this approach is that activated microglia resulting from shaking 
are found to detach from culture vessel and are enriched in suspension, while all the other 
glial cells remain adherent.  
 Materials 
S.No Product Catalogue 
no. 
Company 
Complete media components (maintenance media): 
1.  DMEM SH30022.01 Hyclone, GE Healthcare 
2.  Fetal Bovine Serum SV30160.03 Hyclone, GE Healthcare 
3.  Insulin (Bovine) I0305000 Sigma-Aldrich 
4.  0.1 mM nonessential amino 
acid  
11140- 050 ThermoFisher 








2.  Phosphate buffer saline 
(PBS) 
PB0344 Vivantis 
3.  Trypsin-EDTA solution T4049 Sigma-Aldrich 
4.  70µm cell strainer 352350 BD Biosciences 
5.  0.5M EDTA E-7889 Sigma-Aldrich 
 
 Procedure 
3-day old rat pups were anesthetized using hypothermia and their brain cortices were 
removed and maintained in ice cold PBS. The cortices were cleaned and the meninges were 
carefully removed using fine forceps. The resulting tissue was then mechanically minced 
and transferred to media cocktail (containing basic DMEM with 10% TE and 0.1% DNase) 
for enzymatic digestion at 250rpm for 15mins at 37˚ C. The cell suspension was then 
filtered through a 70µm nylon mesh. The enzymatic mix was replaced by maintenance 
media (described in Table) and the mixed cell culture was seeded into T75 culture flasks 
and can be maintained for 10-12 days. The mixed glial cells were incubated at 37˚C with 
5%CO2 and 95% air incubator.   
Onwards from day 4 in culture, flasks were briefly shaken at low speed for 10 mins, and 
the cell suspension was collected to obtain a floating population of pure microglia cells. 
The suspension was collected and seeded in required plates for further experiments. Media 
was changed every 2 days where fresh media was mixed with conditioned media (1:5 parts) 
and reintroduced into the flasks.  
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 BV2 Cell culture 
 Principle 
 BV2 is a murine microglial cell line (Bocchini et al., 1992, Henn et al., 2009) that was 
initially developed as a suitable alternative to primary microglial cells. Primary microglia 
are difficult to procure in large numbers and provide difficulty in proliferating or 
transfecting due to their sensitivity to environmental changes. As a way to circumvent the 
above and bolster in-depth study of mechanistic pathways, the BV2 cell line has been 
widely used by the microglia community.  
 Materials 
S.No Product Catalogue no. Company 
Complete media components: 
1.  DMEM SH30022.01 Hyclone, GE Healthcare 
2.  FBS SV30160.03 Hyclone, GE Healthcare 









BV2 cells were cultured in DMEM containing 10% FBS and 1% antibiotic antimycotic 
solution, and cultures were maintained in a humidified incubator at 37°C, 5% CO2. To 
maintain the cell line, BV2 cells were maintained in T75 flasks and split every 2-3 days 
when the flask was nearing confluency of ~95%. Briefly, flasks were washed twice with 
1X PBS solution, following a 3 min incubation in an incubator at 37°C with 5ml 1X 
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trypsin-EDTA solution. After trypsin incubation, the enzymatic activity of trypsin was 
quenched by adding 5 ml of complete media (DMEM with 10%FBS). Cell suspension was 
collected from the flask and pelleted down at 1000 rpm, 5mins centrifugation. 
Subsequently cells were re-suspended in required volume of complete DMEM and seeded 
as per the experimental design of downstream experiments.  
 Immunofluorescence  
 Principle 
Immunofluorescence staining is a method to visualise the distribution of specific proteins 
in tissue/cells. It involves the use of a primary antibody against the epitopes of the protein 
to be probed. The primary antibodies are then incubated with a secondary anti-isotope that 
is pre-conjugated to a fluorophore. The fluorophore assists in the detection of the protein 
(Illustration 3-3). 
 
Illustration 3-3 Principle of Immunofluorescence staining  
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 Materials 
S.No Product Catalogue no. Company 
1.  Poly L-lysine P8920 Sigma-Aldrich 
2.  Triton-X 100 T8787 Sigma-Aldrich 
3.  Paraformaldehyde P001 TAAB Laboratories, 
UK 
4.  PBS PB0344 Vivantis 
5.  DAPI D3571 Thermofisher 
6.  Goat serum S-1000 Vector Laboratories 





The rat and mouse brain sections on slides were treated with 0.2% Triton-X 100 followed 
by washing with PBS and blocking with 5% goat serum. Subsequently, brain sections were 
incubated overnight at 4°C with a primary antibody cocktail against H3K9ac and mouse 
anti-CD11b (microglial marker). Sections were further incubated with corresponding 
secondary antibodies for 1h before counterstaining with DAPI and mounting. A similar 
procedure was used to stain mouse brain sections derived from MCAO animal model using 
a primary antibody cocktail against H3K9ac or, TNF-α or, NOS2 or, MAP2 or, IL10 each 
paired with rat anti-CD11b. Sections were further incubated with corresponding secondary 
antibodies followed by counterstaining with DAPI and mounting (ProLong® Diamond 
Antifade Mountant). BV2 cells (approx. 2x104/well) were seeded on coverslips coated with 
poly-L-lysine in 24-well culture plates. Following treatment with LPS and/or SB, cells 
were fixed with 4% paraformaldehyde and treated with 0.2% Triton-X 100 followed by 
washing with PBS and blocking with 5% goat serum. Samples were incubated with the 
primary antibodies against H3K9ac or, pSTAT1 or IL10 overnight at 4°C. Cells were then 
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incubated with corresponding secondary antibodies (inclusive of a FITC conjugated Lectin 
to mark microglia) for 1h and counterstained with DAPI before coverslips were mounted 
on slides. Detailed list of Antibodies is provided in Table 3. Images were captured using a 
a LSM FV1000 (Olympus) equipped with three lasers Ar-Kr (488 nm), He-Ne (646 nm) 
and He-Ne green (532 nm) and a UV diode. 
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Table 3-2 Primary and Secondary Antibodies  
Marker Primary Antibody Secondary Antibody Fluorophore 
Tissue staining 

























Alexa Fluor 488 




Alexa Fluor 488 




Alexa Fluor 488 
CD11b 1:20 






































- - FITC 
  
Table 3-2 Table of Antibodies and detection fluorophores used for immunostaining  
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 Image processing and Analysis 
 Quantification of H3K9ac fluorescence intensity 
BV2 cells from three biological replicates were seeded in 24-wells plates and given 
corresponding treatment with LPS and/or SB. 20-30 confocal images per treatment group 
spread over 3 biological replicates were considered to give a consolidated number of >1000 
cells per treatment group for quantification. 
An analysis method was developed to quantify the H3K9ac immunofluorescence intensity 
observed in each BV2 cell nucleus, in the confocal images taken after 
immunocytochemistry (Figure 3-1). Confocal images (20x) were captured using an LSM 
Olympus FV1000 and opened in ImageJ (v1.50d) for analysis. For every image captured, 
the DAPI channel was converted into a binary image (default) through the auto-
thresholding function. Binary processing of watershed was applied to the image to 
differentiate nuclei. The analyse particles plugin (Schindelin et al., 2015, Schindelin et al., 
2012) was used at size limit of 7 micron-infinity, with circularity 0.00-1.00, excluding 
those on edges. The generated Region(s) of Interest (ROI) were added to the ROI manager. 
Each ROI thus took DAPI as reference and marked each cell’s nucleus. All ROIs were then 
selected and added to the channel with H3K9ac signal, and the region bound by the specific 
ROIs were measured for H3K9ac fluorescence intensity/pixel. This resulted in data 
providing averaged pixel intensity of H3K9ac per ROI, representing individual nuclei.   
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 Quantification of pSTAT3 nuclear bodies  
BV2 cells from three biological replicates were seeded in separate 24-wells plates and 
given corresponding treatment with LPS and/or SB. n>40 confocal images containing 
single nuclei were captured at high magnification (100x) per treatment group spread over 
3 biological replicates and were used for quantification and image analysis  
An analysis method was developed to quantify the punctate staining of pSTAT3 nuclear 
bodies observed in the microglial nuclei from fixed cells using ImageJ (NIH) (Figure 3-
2). Confocal images (z-stacks, variable thickness as per the depth of the nucleus, at 0.55μm 
intervals, LSM FV1000 Olympus, 60x/1.42 oil objective, 5x zoom) were acquired of 
multiple cell nuclei from every treatment group. Confocal images were imported into 
ImageJ as a z-stack with split channels. The Cy3 channel for pSTAT3 fluorescence signal 
was converted into a binary image using the Auto-threshold function 
(method:MaxEntropy, BlackBackground). Binary image stack was further processed by an 
erode function before running it through a 3D objects counter plugin (threshold set to: 255, 
size filter: min 5 voxel) (Bolte and Cordelieres, 2006). Max entropy and summary was 
recorded for each image analysed, and the number of objects/nuclei were noted. The 
resulting Object Map stack was z-projected (Max Intensity). This was overlay on a z-
project of the original Cy3 pSTAT3 stack to manually curate the efficiency of object 
counting for each image. We observed this method to give us a +/- 3 error rate when 








 Co-localization analysis of TNF-α, NOS2 and IL10 expression vs CD11b 
Mice were split into SHAM, 24I/R and 24I/R+SB treatment groups. From n=3-4 mice per 
treatment group, >= 3 confocal images of individual microglial cells were captured, from 
brain regions of cortex, striatum and hippocampus in contralateral and ipsilateral 
hemispheres in each mice respectively and used for analysis and quantification. Data was 
represented as median of percentage colocalisation between TNF-α or, NOS2 or IL10, and 
the microglial marker CD11b.  
Images of microglial cells were captured with 15 slices (optical sectioning) at 0.5µm 
intervals (LSM FV1000 Olympus, 100x/1.42 oil objective, 2x zoom). Images were 
analysed using the IMARISColoc® module (Figure 3-3). Area of microglial cell body was 
defined as a ROI by accounting CD11b intensity. Background falling lower than threshold 
(manually curated) was masked. Coste’s auto-thresholding was applied to all images and 
co-localisation analysis was performed between test channel (TNF-α, NOS2 and IL10) 
compared to ROI defined by CD11b. The percentage of ROI co-localised was the 






Figure 3-3  Work flow of image processing and co-localization analysis 
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 Agarose Gel electrophoresis 
 Principle 
Agarose gel electrophoresis is used to visualize DNA and enable its size separation. Due 
to the negative charge on DNA molecules, DNA moves towards the positive electrode 
through the agarose matrix upon the application of an electric current in the electrophoresis 
chamber, with smaller fragments moving faster than longer ones through the gel. DNA is 
visualized with the help of intercalating dyes such as SYBR safe or ethidium bromide 
(Waring, 1965, Southern, 1979).  
 Materials 
S.No Product Catalogue no. Company 
1.  Certified™ Molecular 
Biology Agarose 
1613102 Bio-Rad 
2.  6X DNA loading dye G1881 Promega 
3.  100bp DNA ladder G6951 Promega 
4.  Tris acetate EDTA buffer 
(TAE, pH 8.0) 
PB0940 Vivantis 
5.  Ethidium bromide (EtBr) 1610433 Bio-Rad 
6.  SYBR® Safe DNA Gel Stain S33102 Thermo-scientific 
 
 Procedure 
A 2% gel was prepared by dissolving 2g of Agarose in 100 ml 1X TAE buffer by heating 
in a microwave. After cooling, 1 µl EtBr or 5 µl SYBR safe was added to the gel while still 
liquid. The solution was poured into a gel tray and an appropriate comb was inserted in the 
gel. After the gel has solidified, it was transferred to an electrophoresis tank and topped up 
with TAE buffer until the gel was completely immersed. 10µl of PCR product/DNA shear 
was mixed with 2µl 6X loading dye and loaded into each well in the gel. 5µl of DNA ladder 
was used also loaded into the well. The gel was run until the dye front reached the end of 
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the gel, and the DNA separation was visualized using the Bio-Rad Image LabTM Imaging 
system.  
 RNA isolation and cDNA conversion 
 Principle 
A widely known protocol for RNA isolation uses an acidic solution containing guanidium 
thiocyanate which lyses cell membranes and other cellular organelles and proteins while 
inhibiting RNases, followed by phase separation using phenol: chloroform, such that RNA 
is collected in the aqueous phase. Qiagen developed the RNeasy midi kit that combines the 
guanidium thiocyanate method with a silica-membrane-based column purification of RNA. 
The RNA molecules (>200 bp) are sequestered in the silica membrane, and can be washed 
followed by their elution to result in pure RNA.  
Purified RNA is then converted into complementary cDNA (cDNA) for downstream 
applications. This process entails incubating the RNA with oligodT primers which can bind 
to the polyA tail of mRNA molecules. In the presence of an RNA-dependent DNA 
polymerase, the mRNA is translated to cDNA.  
 Materials 
S.No Product Catalogue 
no. 
Company 
1.  RNeasy Midi Kit  74104 Qiagen 
2.  Β-mercaptoethanol M6250 Sigma-Aldrich 
3.  Oligo (dT) 15 primer  C1101 Promega 
4.  M-MLV RT 5X buffer  M531A Promega 
5.  M-MLV reverse transcriptase  M1701 Promega 
6.  RNasin  N2515 Promega 
7.  dNTP mix  U1240 Promega 
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 Procedure 
3.11.3.1 RNA isolation 
BV2 cells were seeded in a 6-well plate at a confluency of 1x106 cells/well. Following 
respective drug treatments, total RNA was isolated using the RNeasy midi kit according to 
manufacturer’s protocol. Briefly, cells were washed with warm PBS, and 350 μL of RLT 
buffer (supplemented with 10 μL of β-mercaptoethanol for every 1ml RLT) was added to 
each well of the plate. The sample was incubated on ice for 10min, and transferred to an 
Eppendorf tube. The sample was then aspirated 5-10 times using a syringe and needle. 
700μL of 70% ethanol was added to the sample, and the resulting liquid was added to the 
spin column provided in the kit. After centrifuging the sample at 13,500 rpm for 15sec, 
flow-through was discarded, and 700μL of RW1 buffer was added to the spin column. The 
sample was centrifuged at 13,500 rpm, 15sec, followed by adding 500μL of RPE buffer, 
spinning and discarding flow through. Spin columns were dry spin for 13,500 rpm, 60sec, 
and any residual flow through was discarded. RNA in the spin column was incubated with 
50μL nuclease-free water, and the flow through was collected as pure RNA. RNA was 
quantified and judged for its quality using a Spectrophotometer (Nanodrop, Model No. 
ND1000, Thermo Scientific). The A260/A280 absorbance ratio is falling within a range of 
1.8-2.0 indicated quality RNA with minimum contaminants. RNA was aliquoted and stored 
at -80°C.  
3.11.3.2 cDNA synthesis 
Following RNA quantification, cDNA synthesis was performed by first mixing 2μg of 
RNA, and 2μL of Oligo (dT) 15 primer at 70°C for 5min in a thermal cycler (Bio-rad), 
followed by the addition of an aliquoted master mix consisting of 5μL of Moloney Murine 
Leukemia Virus (M-MLV) RT 5X buffer, 1μL of M-MLV reverse transcriptase, 0.7μL of 
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RNase inhibitor (RNasin), and 0.5μL of dNTP mix. The reaction volume is topped up to 
25μl with nuclease free water and run on a set-up program of maintaining at 42°C for 1hr; 
70°C for 10 mins followed by standby at 4°C. cDNA was stored at -20°C. 
 Quantitative Reverse Transcriptase-Polymerase Chain Reaction (qRT-PCR) 
 Principle 
 
Figure 3-4 Representative image showing the amplification plot and dissociation curve 
of β-actin gene analysed through qPCR 
 
The real-time PCR machine is a highly sensitive nucleic acid quantification tool which can 
detect DNA even at low copy numbers. Quantitative PCR is based on the principle of 
quantifying DNA amplification by using intercalating dyes such as SYBR green, which 
can selectively associate with double strand DNA, thus, enabling the tracking of the DNA 
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quantity in real time. It has a fluorescent detector which measures the increase in the 
fluorescent intensity of SYBR green associated with double strand DNA present in the 
reaction at any given time. The amplification plot of an example housekeeping gene – β-
actin is illustrated above (Figure 3-4), with the readout of the fluorescent intensity 
changing over the progression of the PCR reaction. A typical PCR reaction consists of 
cDNA template, primers specific to the 5’ and 3’ strands of the specific gene to be probed, 
and the Fast SYBR Green master mix. The PCR reaction involves repeated cycles of 
discrete temperature steps which allow for melting of the double stranded DNA into single 
strands (denaturing-1 sec@ 95 °C), annealing of primers to the specific cDNA template, 
and the amplification carried out by the DNA polymerase (20 sec@ 60 °C). The 
fluorescence signal is initially below detectable values (baseline), which is followed by an 
exponential growth of amplicons (exponential phase) and the plateau phase. The threshold 
is set at ½ exponential phase and is kept constant for all samples. The cycle at which the 
fluorescent intensity of the reaction crosses the threshold is called the cycle threshold (CT).  
qPCR analysis has been carried out using the 2-ΔΔCt method using the formula from 
published protocols (Schmittgen and Livak, 2008): 
Fold change = 2-ΔΔCt 
ΔCT = CT gene of interest - CT internal control 
ΔΔCT=ΔCT treatment - ΔCT control 
An additional step, called the ‘dissociation stage’ can be added to the thermal cycler 
program. It is used to check the specificity of primers, and that a single amplicon has been 
amplified. The dissociation stage consists of gradually increasing the temperature of the 
reaction to enable dissociation of the double stranded amplicon until a sharp dip is seen in 
the fluorescent intensity (raw dissociation curve) at the melting temperature (Tm). The 
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dissociation curve is usually represented in derivative form, with a single peak indicating 
a single amplicon.  
 Materials 
S.No Product Catalogue 
no. 
Company 
1.  Fast SYBR Green 2X Master Mix 
Contains: 
1. AmpliTaq® Fast DNA 
Polymerase 
2. SYBR® Green I dye 
3. Deoxynucleotides (dNTPs) 
4. Uracil-DNA Glycosylase 
(UDG) 
5. Passive internal reference 
(based on ROX dye) 
6. Proprietary buffer 
 
4385612  Applied 
Biosystems 
2.  Nuclease-free water 129114 Qiagen 
3.  Forward primer (10mM)  IDT 
4.  Reverse primer (10mM)  IDT 
 
 Procedure 
PCR analysis for gene expression analysis was carried out using 1μL of 1:10 diluted cDNA 
(using nuclease free water) added to a reaction mixture comprising of 5μL Fast SYBR 
Green 2X Master Mix, 0.5μL each forward and reverse primer (10mM) (Table 1, 2) topped 
up to 10μL with nuclease free water. The PCR was carried out in the Applied Biosystems 
7900HT Fast Real-Time PCR machine (Life Technologies) using the standard Fast 
protocol. PrimerBank ID’s accompany primers which were acquired from PrimerBank 
(Table 3-3) (Spandidos et al., 2010).  
76 
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Table 3-3 Primer sets used for qPCR gene expression studies 
   




 Forward Primer (5’-3’) Reverse Primer (3’-5’) 
Primer 
Bank ID 
Fcrlb ACCACCATCTTCAAGGGAGAG TACCAGAGAGTGCTAATGGGC 134288908c1 
Il10 CCAAGCCTTATCGGAAATGA GCTCCACTGCCTTGCTCTTA  
Il4ra TCTGCATCCCGTTGTTTTGC GCACCTGTGCATCCTGAATG 26329959a1 
Il6 TCCACGATTTCCCAGAGAAC AGTTGCCTTCTTGGGACTGA  
Irf1 ATGCCAATCACTCGAATGCG TTGTATCGGCCTGTGTGAATG 6680467a1 
Itpr1 CGTTTTGAGTTTGAAGGCGTTT CATCTTGCGCCAATTCCCG 26339686a1 
Mafb TTCGACCTTCTCAAGTTCGACG TCGAGATGGGTCTTCGGTTCA 23308601a1 
Nos2 CCCTGGCTAGTGCTTCAGAC CCTGTGTTCCACCAGGAGAT  
Socs1 CTGCGGCTTCTATTGGGGAC AAAAGGCAGTCGAAGGTCTCG 6753424a1 
Stat1 TCACAGTGGTTCGAGCTTCAG GCAAACGAGACATCATAGGCA 31543778a1 
Stat3 CAATACCATTGACCTGCCGAT GAGCGACTCAAACTGCCCT 13277852a1 
Tnf-α CGGACTCCGCAAAGTCTAAG CGTCAGCCGATTTGCTATCT  
β-actin AGCCATGTACGTAGCCATCC CTCTCAGCTGTGGTGGTGAA  
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 Chromatin Immunoprecipitation Assay 
 Principle 
Chromatin Immunoprecipitation is a technique to study Protein-DNA binding. It involves 
crosslinking all DNA-bound proteins such as histones and transcription factors to DNA, 
followed by DNA shearing and immunoprecipitation using antibodies to specific proteins. 
The crosslinked protein-DNA complex selectively pulled down by the specific antibody is 
sequestered using agarose beads. The DNA linked to the protein is then eluted, quantified 
using qPCR and extrapolated to quantify the enrichment of the pulled down sequence with 
respect to genomic DNA (Illustration 3-4).  
 Materials 





17-371 Merck Millipore 
2.  Paraformaldehyde P6148 Sigma-Aldrich 
3.  Glycine G5417 Sigma-Aldrich 
4.  
Protein A Agarose/Salmon 
Sperm beads  
16-157 Merck Millipore 
5.  





6.  QIAquick PCR purification Kit 28104 Qiagen 
7.  





8.  Nuclease-free water 129114 Qiagen 
9.  Forward primer (10mM)   






Illustration 3-4 Principle of Chromatin Immunoprecipitation (ChIP) assay. 
X/R=Gene specific amplicon from ChIPed DNA/Gene specific amplicon from genomic DNA  
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 Procedure 
Chromatin immunoprecipitation was performed using the Chromatin Immunoprecipitation 
Kit (EZ-ChIP) according to manufacturer’s protocol. Protein-DNA were cross-linked in 
cultured BV2 microglial cells with 1% paraformaldehyde for 10 mins after which the 
reaction was quenched using 2.5mM Glycine. The cells were lysed on ice and the crude 
extracts were sonicated to shear cross-linked DNA into smaller fragments (200–1000 bp) 
which was verified in an agarose gel. This was followed by incubating the sheared DNA 
with Protein A Agarose/Salmon Sperm beads to preclear non-specific interactions, 
followed by incubation of aliquots with relevant antibodies (Table 3-4) such as H3K9ac 
(Cat#07-352, Millipore), H3 (Cat# AB1791, Abcam), PolII (Cat# 05-623, Millipore) and 
IgG with shaking at 4°C, overnight; Protein A Agarose/Salmon Sperm beads were used to 
pull down antibody bound Protein-DNA for 2h (4°C with shaking) and treated to 
subsequent washes (High salt wash buffer, Low salt wash buffer, LiCl wash buffer and 
then TE buffer) before elution. Crosslinking was then reversed, and the 
immunoprecipitated DNA fragments were purified using a QIAquick PCR Purification Kit 
according to manufacturer’s protocol. Primers were designed using Primer-BLAST (Ye et 
al., 2012) to probe 100bp genomic regions in close vicinity downstream of the transcription 
start site (TSS), where the strongest enrichment of H3K9ac/H3 was expected (Table 3-4). 
Primer specificity was checked using MFEPrimer-2.0 (Qu et al., 2012). The DNA samples 
were then analysed through a qRT-PCR (Fast program - same as above) and analysed with 
reference to 1% input DNA (sample without antibody pull-down). Normal rabbit IgG (Cat# 
12-370; Upstate Biotechnology) served as a negative control to verify reaction specificity 




Table 3-4 Primer sets used for ChIP-qPCR 
  
Primer sets used for ChIP-qPCR analysis (mouse) 
Gene 
Name 
Forward Primer  Reverse Primer  
Fcrlb AAATCCTGCTGATGCCCCC ATGCCTCCAACCTCTACCGA 
Il10 GCCTGCTCTTACTGACTGGC AGCTCTAGGAGCATGTGGCT 
Il6 TGTGGGATTTTCCCATGAGTCT TATCGTTCTTGGTGGGCTCC 
Nos2 GGGGACTCTCCCTTTGGGAA GGGGCCAGAGTCTCAGTCTT 
Stat1 GTCTGTCAAAGCTCCCTGG CTCACTCACTCACTGCACG 
Tnf-α GCCAGTGAGTGAAAGGGAC CTAGCCAGGAGGGAGAACAG 
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 Western Blot 
 Principle 
Western Blotting is a technique to identify protein and quantify its levels in cells or tissue. 
It involves denaturing proteins by removing their secondary and tertiary structure and 
associating with negatively charged SDS so that they move towards the positive electrode. 
The denatured proteins are separated based on the length of their polypeptide, by running 
it through a polyacrylamide gel. The resolved proteins are then transferred to a 
polyvinylidene difluoride (PVDF) membrane and probed with specific primary antibodies, 
and further appropriate secondary antibodies conjugated to HRP for detection. A 
housekeeping gene such a β-actin serves as a reference.  
 Materials and Equipment 
S.No Product Catalogue no. Company 
Protein extraction and quantification 
1.  MPER protein extraction reagent 78501 Thermo-Scientific 
2.  Protease inhibitors 88665 Thermo-Scientific 
3.  Phosphatase inhibitors 88667 Thermo-Scientific 
4.  
Bio-Rad Protein Assay Dye Reagent 
Concentrate 
500-0006 Bio-Rad 




Sodium dodecyl sulfate-Polyacrylamide gel electrophoresis (SDS-PAGE) 
6.  
10X Tris/glycine/SDS electrophoresis 
buffer: Running buffer 
161-0732 Bio-Rad 
7.  TEMED (tetramethylethylenediamine) 161-0800 Bio-Rad 
8.  
10% Sodium Dodecyl Sulfate (SDS) 
Solution 
PB0640 Vivantis 
9.  Ammonium Persulfate (APS) 161-0700 Bio-Rad 
10.  30% Acrylamide/Bis Solution, 29:1 161-0156 Bio-Rad 
11.  2X Laemmli protein loading buffer 161-0737 Bio-Rad 
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12.  
PageRuler™ Prestained Protein Ladder, 
10 to 180 kDa 
26616 Thermo-Scientific 
Semi-dry electrophoretic transfer 
13.  Immunoblot PVDF membrane 88520 Thermo Scientific 
14.  Blotting paper  88605 Bio-Rad 
15.  
Trans-blot SD semi-dry 
electrophoretic transfer cell 
 Bio-Rad 
16.  




17.  Bovine Serum Albumin (BSA) SH30574.02 GE Healthcare 
18.  











20.  CL-XPosure Film 34091 Thermo Scientific 




Primary and Secondary Antibodies 
 Gene Primary Antibody Secondary antibody 
Dete
ctor 





























8% resolving gel (15ml): 5% stacking gel (6ml):  
H2O: 6.9ml 
30% acrylamide mix: 4ml 
1.5M Tris buffer (pH 8.8): 3.8ml 
10% SDS: 150μl 
10% ammonium persulfate (APS): 150μl 
T.E.M.E.D: 9μl 
H2O: 4.1ml  
30% acrylamide mix: 1ml  
1.5M Tris (pH 6.8): 750μl  
10% SDS: 60μl  




Total protein was extracted from BV2 cell cultures using the MPER protein extraction 
reagent containing protease and phosphatase inhibitors, and concentrations were analyzed 
using (Bradford assay; Bio-Rad Laboratories) following which proteins (30µg) were run 
on a 8% SDS-polyacrylamide gels and transferred to polyvinylidene difluoride (PVDF) 
membranes. The membranes were subsequently blocked using 5% BSA and probed with 
rabbit anti-pSTAT (1:1500; Cat# ab30645; Abcam), overnight at 4°C. Same blots were re-
probed with rabbit anti-STAT1 (1:200; Cat#ab2415; Abcam) following which Horseradish 
peroxidase (HRP)-conjugated secondary antibodies were added onto membranes for 1 h at 
room temperature. Membranes stripped of antibody were incubated with anti-β-actin 
mouse monoclonal antibody (Cat#A1978, Sigma–Aldrich). Blots were developed with the 
chemiluminescence detection system (Supersignal West Pico Horseradish Peroxidase 
Detection Kit for pSTAT1 and STAT1; and ECL Western blotting substrate for β-actin. 
The blots were developed on a film, subsequently measured for signal intensity using 
Quantity One Software (Bio-rad, CA, USA) version 4.4.1. 
 Statistical Analysis 
Data derived from three to four independent experiments were used for statistical analysis 
and presented as Mean ± SEM, or Median ± Interquartile Range. Statistical analysis was 
carried out by ANOVA, Tukey’s post-hoc test, unless specified otherwise. All statistical 








Characterization of H3K9ac in microglia in a healthy brain  
 Global H3K9ac levels decrease in microglia during its development from the 
amoeboid to the ramified phenotype 
To begin characterizing the histone mark H3K9ac in microglia, we first aimed to assess in 
vivo global H3K9ac expression pattern in microglia in healthy rat brains. Microglial cells 
undergo a phenotypic and functional change during postnatal development, which is 
marked by a change in their morphology from rounded ‘amoeboid’ cells to ‘ramified’ cells 
with finer processes extending outwards surveying the brain parenchyma (Leong and Ling, 
1992). Brains were harvested from heathy post-natal rats of ages 1, 5, 7 days and 4 weeks, 
and the sections were immune-stained for H3K9ac and microglial marker CD11b (n=3 
each) (Figure 4-1). Microglia in the corpus callosum of respective brain sections were 
analysed for their H3K9ac expression.  
Microglial cells exhibited varying morphology with respect to ages of the rat, i. e. 
amoeboid shape during early post-natal days of 1, 5, 7D and ramified in the corpus 
callosum of 4-week rat brains. H3K9ac expression was present in day 1, 5, 7 amoeboid 
microglia. H3K9ac was barely detectable in microglia from 4-week old rat brains, 
suggesting that global H3K9ac levels decrease in microglia during its transition from 






Figure 4-1 Microglial cells (red) observed in the corpus callosum in 1, 5, 7 days and 4-
week old rat brains.  
Confocal images with increasing magnifications of the corpus callosum in ages of 1, 5, 7 days and 
4 weeks old postnatal rat brains respectively, were observed for a temporal study of H3K9ac 
expression in microglial cells. Microglia exists in a rounded morphology typical of amoeboid 
microglia during day 1, 5, and 7, which transition to ramified microglial morphology at 4 weeks. 
CD11b (red, white arrows) marks microglia. DAPI marks nuclei (blue). H3K9ac is marked in green. 






Figure 4-2 Global H3K9ac levels decrease during microglial transformation from 
amoeboid to ramified phenotype  
H3K9ac levels were assessed in microglial cells in the corpus callosum of rat brains aged 1, 5, 7 
days and 4-weeks old respectively. Immunofluorescence analysis of fixed brain tissue indicates that 
global H3K9ac levels decrease in microglia during its transformation from amoeboid to ramified 
during post-natal brain development. CD11b (red, white arrows) marks microglia. DAPI marks 
nuclei (blue). H3K9ac is marked in green. n=3. Row 4 presents a zoom-up of the indicated inset 
with CD11b (red, white arrows) and H3K9ac (green). Scale bar represents 50µm and 10µm (inset). 
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Characterization of H3K9ac in microglia in the ischemic mouse brain  
 H3K9ac levels are upregulated in activated microglia in the infarct and peri-
infarct zone (penumbra) following 24I/R transient MCAO in mice  
H3K9ac levels were evaluated in the cortex and striatum of stroke brain caused by transient 
24 Ischemia/Reperfusion (I/R) Middle cerebral artery occlusion (MCAO), as the MCAO 
stroke is primarily seen to affect the cortex and striatum. High H3K9ac levels were mostly 
detected in cell nuclei (predominantly neuron) in the brain, with the number of H3K9ac 
expressing nuclei markedly decreasing in the infarct zone of cortex and striatum (Figure 
4-3A). The infarct and penumbra regions in the stroke brain could be distinguished by the 
H3K9ac enrichment in predominant neuronal nuclei (Figure 4-3B). Further quantification 
confirmed decreased number of nuclei displaying H3K9ac expression in the infarct region 
(Figure 4-3C) when compared to the penumbra zone.  
Spatiotemporal changes in microglial morphology were observed in the infarct and 
penumbra regions of the cortex, striatum and hippocampus indicating microglial activation 
in response to MCAO-induced ischemia (Figure 4-3B, 4-4). H3K9ac levels were hardly 
detectable in microglia in sham-operated mouse brains and the contralateral cerebral 
hemisphere. In contrast, H3K9ac was found to be upregulated in activated microglia that 
were distributed in the infarct and peri-infarct junction of MCAO ischemic brain (Figure 
4-4). A significant proportion of microglia in regions of cortex, hippocampus and striatum 
in the ipsilateral hemisphere showed an upregulation of H3K9ac when compared to 
microglia from the respective contralateral hemisphere (Figure 4-5; 24I/R MCAO, n=3; 
Contralateral vs Ipsilateral, Two-way ANOVA with Sidak’s post hoc test; Cortex, 
****p<0.0001; Hippocampus, *p=0.012; Striatum, **p=0.0019).   
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Figure 4-3 H3K9ac is downregulated in the infarct in ipsilateral hemisphere of 24I/R 
MCAO mice brains 
(A) A coronal brain section with immunofluorescence staining of H3K9ac (green), CD11b 
microglial marker (red) and nuclei with DAPI (blue) shows the loss of H3K9ac in cellular nuclei in 
ipsilateral cortex and striatum regions (dotted white lines) in mice subjected to 1h ischemia by 
transient middle cerebral artery occlusion (tMCAO) followed by 24h reperfusion (24I/R) (B) 
Differential global acetylation levels in nuclei from the infarct (white dotted lines) vs penumbra 
(yellow dotted lines). Activated microglia observed near the infarct penumbra junction displayed an 
upregulation of H3K9ac levels (circles; yellow-penumbra; white-infarct). (C) Image quantification 
determining H3K9ac intensity per cell nucleus in infarct and penumbra regions (marked) display 




Figure 4-4 H3K9ac is upregulated in activated microglia in the ipsilateral hemisphere 
of the 24I/R MCAO mice 
Representative image of upregulated H3K9ac (green) in activated microglia (CD11b expression, 
red) in cortex, striatum and hippocampus of ipsilateral hemisphere following 24I/R tMCAO in mice 
when compared to corresponding contralateral hemisphere, and SHAM mice. Note that H3K9ac 
expression is hardly detectable in microglia distributed in the brain of contralateral hemisphere, and 








Figure 4-5 Quantification of percentage of microglia expressing H3K9ac in 24I/R 
MCAO mice brains 
Histogram showing percentage of microglia with upregulated H3K9ac in the cortex, striatum and 
hippocampus respectively. Data represented as mean ± SEM, *p<0.05, **p <0.01; ****p<0.0001. 




 H3K9ac levels are upregulated in LPS activated microglia in vivo  
It was further investigated if the upregulation of H3K9ac in activated microglia in infarct 
regions in response to stroke is specific to ischemic stroke or a consistant response of 
microglial activation. Microglial cells in the corpus callosum (which shows consistent 
microglial accumulation) in 4-weeks old rat brains were activated by intraperitoneal 
administration of LPS and subsequently analysed for H3K9ac levels. In response to LPS 
treatment, microglial cell morphology was transformed from ramified to activated (with 
characteristic shorter processes). H3K9ac was upregulated in activated microglia in the 
corpus callosum of 4-week old wistar rats in comparison to that of age-matched saline 






Figure 4-6 H3K9ac is upregulated in activated microglia in rat brain following LPS 
administration  
Activation of microglia through intraperitoneally injected lipopolysaccharide (LPS) also induced 
upregulation of H3K9ac expression (green) in activated microglia (CD11b, red) located in the 
corpus callosum of a 28D rat brain. White arrows indicate microglia. DAPI (blue) staining nuclei; 
n=3. Scale bar, 20 µm. 
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Neuroprotection imparted by HDAC inhibitor sodium butyrate (SB) in mouse model 
of ischemic stroke 
 SB supresses upregulation of H3K9ac levels in activated microglia in the 
ipsilateral cortex of 24I/R ischemic mice 
A schematic with the timeline of SB treatment is provided in (Illustration 3-1). To 
determine whether a microglia-dependent mechanism was involved in SB-mediated 
neuroprotection, activated microglial cells were probed for changes in H3K9ac levels in 
ischemic mice treated with SB (Figure 4-7). Microglia were observed in the cortex, 
hippocampus, and striatum from contralateral and ipsilateral cerebral hemispheres in SB-
treated and untreated ischemic mice (24I/R). In contrast to the upregulation of H3K9ac in 
activated microglia in 24I/R MCAO mice, upregulation of H3K9ac levels was not evident 
in morphologically active microglia from SB-treated ischemic mice (Figure 4-7, 4-8; 
MCAO (24I/R (n=3), 24I/R+SB (n=3)); Contralateral vs Ipsilateral, Two-way ANOVA 
with Tukey’s post hoc test; 24I/R, Cortex ****p<0.0001, Striatum *p=0.0148, 
Hippocampus ***p=0.0008) 24I/R Ipsi vs 24I/R+SB Ipsi, Cortex ****p<0.0001, Striatum 
**p=0.0036, Hippocampus ****p<0.0001). This indicates the ability of HDAC inhibitor 





Figure 4-7 Sodium butyrate suppresses H3K9ac levels in microglia in 24I/R MCAO. 
Morphologically activated microglia (CD11b, red) observed in the infarct regions in the cortex, 
striatum and hippocampus of 24I/R MCAO mice and SB treated 24I/R MCAO mice were probed 
for the histone mark H3K9ac (green). Representative immunofluorescence images depicting 
activated microglia in infarct regions of ipsilateral hemisphere in 24I/R MCAO mice brains display 
an induction of H3K9ac when compared to microglia in respective contralateral hemisphere. 
H3K9ac levels were suppressed in morphologically activated microglia in ipsilateral brain of SB 
treated MCAO mice, consistently observed in the cortex, hippocampus and striatum. White arrows 








Figure 4-8 Quantification of percentage of microglia expressing H3K9ac in 24I/R 
MCAO mice and those treated with sodium butyrate 
Histogram showing decreased number of H3K9ac expressing microglia (in %) in ipsilateral 
hemisphere of mice undergone 24I/R MCAO with SB treatment when compared to the upregulation 
seen in ipsilateral hemisphere of mice undergone MCAO with 24I/R without SB treatment. Data 
represented as mean ± SEM, n=3; *p<0.05, ** p<0.01; ***p<0.001; ****p<0.0001. Two-way 






 Sodium butyrate confers neuroprotection in ischemia in 24I/R MCAO mice 
To test for neuroprotective effects of HDAC inhibition in mice induced with ischemic 
stroke, microtubule-associated protein 2 (MAP2), a neuron specific cytoskeletal protein 
marking healthy neuronal dendrites was used to identify degenerating neurons in infarct 
regions in the cortex, striatum, and hippocampus of 24I/R MCAO brains. Additionally, 
mice were subjected to a double dose of SB, the HDAC inhibitor (1h prior and 6h after 
transient ischemia) during MCAO. Mice undergone sham surgery were included as the 
negative control.  
Brains were harvested 24h after ischemia induction, and the expression of MAP2 was 
analysed in cortex, striatum and hippocampus in the brains of sham mice, 24I/R MCAO 
ischemic mice, and those of 24I/R MCAO treated with SB (Fig 2A). 
No change was observed in MAP2 intensity in sham mice brains comparing between the 
two hemispheres (Figure 4-9). The intensity of MAP2 expression in the brains of mice 
subjected to 24I/R MCAO was found to be decreased in the infarct zone observed in the 
ipsilateral cerebral hemisphere as compared to the contralateral cerebral hemisphere 
(Figure 4-10). However, the decrease in MAP2 expression was rescued in the ischemic 
brain by SB treatment. Marked expression of MAP2 in the infarct zone replete with 
activated microglial cells was found in the cortex, hippocampus, and striatum of ischemic 
brain after SB treatment. Quantification of MAP2 intensity in whole brain sections by 
ImageJ (Schindelin et al., 2015) confirmed observations (Figure 4-11) Sham (n=3), 24I/R 
(n=3), 24I/R+SB (n=3)); Contralateral vs Ipsilateral, Two-way ANOVA with Sidak’s post 
hoc test; 24I/R MCAO, **p=0.0088). This result is indicative of the neuroprotective ability 
of HDAC inhibitors in the ischemic brain.  
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Figure 4-9 Immunofluorescence staining of MAP2 (green) in mice brain sections 
following sham surgery 
Immunofluorescence staining of MAP2 in mice brain sections (cortex, hippocampus, and striatum) 
following sham surgery. No significant difference in MAP2 intensity (green) was found comparing 
ipsilateral hemisphere to its corresponding contralateral hemisphere. DAPI (blue) marking nuclei, 








Figure 4-10 (A-C) Sodium butyrate (SB) confers neuroprotection in MCAO with 24h 
Ischemia/Reperfusion (Pages 99-101). 
Immunofluorescence analysis shows the MAP2 expression in different brain regions of cortex, 
hippocampus and striatum (contralateral vs ipsilateral) of mice in response to transient 24h 
ischemia/reperfusion (tMCAO) compared to mice treated with SB (double dose 300 mg/kg, i.p.-1h 
before ischemia and 6h after onset of ischemia). 24I/R MCAO mice display a loss of MAP2 (green) 
in the infarct induced in ipsilateral cortex (A), hippocampus (B) and striatum (C) upon 24I/R 
tMCAO, along with a presence of activated microglia (red, white arrows). However, SB treatment 
prevented the loss of MAP2 in the ipsilateral cortex, hippocampus and striatum. MAP2 expression 
is seen to remain consistent to contralateral, even in the presence of morphologically activated 
microglia (red, white arrows) present in the representative images. Scale bars, 200 µm (low mag) 





Figure 4-11 Quantification of MAP2 intensity in24I/R MCAO mice brains following 
sodium butyrate treatment 
Quantification of MAP2 intensity spanning contralateral vs ipsilateral hemispheres of whole brain 
sections from tMCAO 24I/R mice, where loss of MAP2 expression is rescued in the SB treated 
group. MAP2 intensity quantification was performed using ImageJ. Data represented as mean ± 
SEM, n=3 mice/group; ** p<0.01. Two-way ANOVA, Sidak’s post hoc test. 
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 Sodium butyrate suppresses TNF-α expression in microglia in 24I/R MCAO 
ischemic mice 
Tumor necrosis factor-alpha (TNF-α) is a cell signalling molecule and a hallmark of an 
acute inflammatory response in various neuropathologies. Upregulation of TNF-α 
expression in microglia is indicative of its pro-inflammatory activation and is concomitant 
with an M1 activation phenotype (Walker and Lue, 2015, Kroner et al., 2014).  
TNF-α was upregulated in activated microglia in the ipsilateral regions of the cortex, 
hippocampus and striatum of 24I/R MCAO mouse brains. Subsequent analysis in activated 
microglia in the infarct regions of the ischemic brain after SB treatment revealed that  TNF-
α was hardly detectable (Figure 4-12) when compared to its upregulation in activated 
microglia in 24I/R MCAO mice (Figure 4-13, TNF-α; Median±1.4286 x median absolute 
deviation (MAD) of %ROI (CD11b) colocalisation; 24I/R Ipsi (n=3) vs 24I/R+SB Ipsi 
(n=3); TNF-α (cortex, 1.535±0.17 vs 0.44±0.148, **p=0.0096; Hippocampus, 0.89±0.237 






Figure 4-12 Sodium butyrate treatment suppressed microglial pro-inflammatory 
mediator TNF-α in mice subjected to 24h I/R MCAO (Page 104). 
Representative images of TNF-α immunofluorescence in activated microglia in the cortex, 
hippocampus and striatum of untreated and SB treated mice subjected to tMCAO respectively. 
Brains of 24I/R MCAO mice untreated, and SB treated, were subjected to 24I/R tMCAO and 
cryosectioned at 20µm. Immunofluorescence analysis of microglia (CD11b; red, white arrows) for 
TNF-α (green) displayed an induction of TNF-α in ipsilateral cortex, hippocampus and striatum in 
24I/R MCAO mice in comparison to little or no expression of TNF-α in microglia in respective 
contralateral region. Morphologically activated microglia observed in the ipsilateral cortex, striatum 
and hippocampus of SB treated mice, in contrast, displayed little or no induction of TNF-α 
expression in response to transient ischemia. Confocal optical sectioning was performed with 
representative images shown as a z-projection of merged channels accompanied with a z-projection 





Figure 4-13 Quantification of %TNF-α colocalised with microglial marker CD11b in 
24I/R MCAO mice compared to sodium butyrate treated, indicated downregulation of 
TNF-α in activated microglia upon SB treatment  
Analysis of 3-5 images per region in either hemisphere per animal/treatment group was done by 
defining a region of interest (ROI) marked by the CD11b (red) channel. Coste’s thresholding 
approach was used for automatic thresholding of each image. Co-localisation is represented by the 
% ROI (CD11b) co-localised with TNF-α, and is plotted as median ± 1.4826 x median absolute 
deviation (MAD) in the quantitative representation. 
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 Sodium butyrate suppresses NOS2 expression in microglia in 24I/R MCAO 
ischemic mice 
Nitric Oxide synthase 2 (NOS2) gene catalyses the synthesis of Nitric Oxide (NO) from L-
arginine which is a second messenger crucial to the pro-inflammatory response elicited by 
immune cells (Korhonen et al., 2005). In the brain, NO is a messenger molecule transiently 
produced by neurons in selective regions for their function. However, upon inflammation, 
NO is solely produced by microglial cells in the brain (Béchade et al., 2014). While 
microglial Reactive Oxygen Species (ROS), derived from NO are cytotoxic and targeted 
towards killing pathogens to protect the brain, excessive NO production due to chronically 
active microglia can eventually cause tissue damage (Korhonen et al., 2005, Chhor et al., 
2013). NOS2 expression is indicative of the pro-inflammatory M1 microglial activation 
phenotype (Chhor et al., 2013).  
Pro-inflammatory mediator NOS2 was upregulated in activated microglia in the ipsilateral 
cortex, hippocampus and striatum of 24I/R MCAO mice brains when compared to 
corresponding contralateral hemisphere (Figure 4-14). However, similar to TNF-α 
expression, NOS2 expression was downregulated in activated microglia of ischemic mice 
treated with SB (Figure 4-15; NOS2; Median±1.4286xMAD of %ROI (CD11b) 
colocalisation; 24I/R Ipsi (n=3) vs 24I/R+SB Ipsi (n=4) (cortex, 3.155±0.8 vs 0.59±0.255; 





Figure 4-14 Sodium butyrate treatment suppressed microglial pro-inflammatory 
mediator NOS2 in mice subjected to 24h I/R MCAO (Page 107)  
Representative images of NOS2 immunofluorescence in activated microglia in the cortex, 
hippocampus and striatum of untreated and SB treated mice subjected to tMCAO respectively. 
Brains of untreated and SB treated mice were subjected to 24I/R tMCAO and cryosectioned at 
20µm. Immunofluorescence analysis of microglia (CD11b; red, white arrows) for NOS2 (green) 
displayed an induction of NOS2 in ipsilateral cortex, hippocampus and striatum in untreated 24I/R 
MCAO mice in comparison to little or no expression in microglia in respective contralateral region. 
Morphologically activated microglia observed in the ipsilateral cortex, striatum and hippocampus 
of SB treated mice, in contrast, show little or no induction of NOS2 expression in response to 
transient ischemia. Confocal optical sectioning was performed with representative images shown as 
a z-projection of merged channels accompanied with a z-projection of only, NOS2. 24I/R MCAO 





Figure 4-15 Quantification of %NOS2 colocalised with microglial marker CD11b in 
24I/R MCAO mice compared to sodium butyrate treated mice indicated downregulation 
of NOS2 in activated microglia upon SB treatment  
Analysis of 3-5 images per region in either hemisphere per animal/treatment group was done by 
defining a region of interest (ROI) marked by the CD11b (red) channel. Coste’s thresholding 
approach was used for automatic thresholding of each image. Co-localisation is represented by the 
% ROI (CD11b) co-localized with NOS2, and is plotted as median ± 1.4826 x median absolute 
deviation (MAD) in the quantitative representation.  
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 Sodium butyrate upregulates IL10 expression in microglia in 24I/R MCAO 
ischemic mice 
IL10 is one of the major anti-inflammatory cytokines, that is indicative of a M2 phenotype 
in macrophages/microglia (Chhor et al., 2013).  
The HDAC inhibitor-mediated downregulation of pro-inflammatory mediators, TNF-α and 
NOS2, was concomitant with an upregulation of anti-inflammatory cytokine, IL10 in 
activated microglia observed in ischemic brains after SB treatment when compared to 
untreated ischemic mice (Figure 4-16). Quantification of the percentage of co-localization 
of TNF-α, NOS2 with CD11b microglia marker indicated a downregulation of the pro-
inflammatory mediators in response to SB treatment. In contrast, an increase in the 
percentage of co-localization of IL10 with microglia (CD11b) was observed in response to 
SB treatment, affirming the shift towards an anti-inflammatory phenotype of microglia 
(Figure 4-17, IL10; Median±1.4286MAD of %ROI (CD11b) colocalisation; 24I/R Ipsi 
(n=3) vs 24I/R+SB Ipsi (n=3); (cortex, 1.21±1.734 vs 6.26±0.385, *p=0.036; 
Hippocampus, 1.15±1.475 vs 10.17±3.09; Striatum, 0.69±0.845 vs 6.3±3.484; Two-way 





Figure 4-16 Sodium butyrate treatment upregulates microglial anti-inflammatory 
mediator IL10 expression in mice subjected to 24h I/R MCAO (Page 11010)  
Morphologically activated microglia observed in the ipsilateral cortex, hippocampus and striatum 
of untreated and SB treated mice in response to 24I/R MCAO show induction of IL10. Microglia 
(CD11b; red, white arrows) in both, the contralateral and ipsilateral hemispheres of SB treated mice 
displayed a stark increase in IL10 expression when compared to untreated mice subjected to 
tMCAO. DAPI (blue) stain nuclei. Confocal optical sectioning was performed with representative 
images shown as a z-projection of merged channels accompanied with a z-projection of only IL10. 




Figure 4-17 Quantification of %IL10 colocalised with microglial marker CD11b in 
24I/R MCAO mice compared to sodium butyrate treated, indicated upregulation of 
IL10 in activated microglia upon SB treatment 
Analysis of 3-5 images per region in either hemisphere per animal/treatment group was done by 
defining a region of interest (ROI) marked by the CD11b (red) channel. Coste’s thresholding 
approach was used for automatic thresholding of each image. Co-localisation is represented by the 
% ROI (CD11b) co-localized with IL10, and is plotted as median ± 1.4826 x median absolute 




Investigation of the immediate effects of HDAC inhibition via sodium butyrate in 
activated microglia at the molecular level 
 Sodium butyrate treatment upregulates H3K9ac levels in activated microglia 
in vitro  
H3K9ac enrichment at gene promoters is maintained by crosstalk between HDACs and 
HATs family of proteins (Shahbazian and Grunstein, 2007). BV2 microglial cells were pre-
treated with SB to confirm that HDAC inhibitor SB modulates H3K9ac levels. 
Immunofluorescence revealed that HDAC inhibition resulted in a global upregulation of 
H3K9ac in LPS activated microglia, confirming the role of HDACs in negative regulation 
of H3K9ac levels in microglia (Figure 4-18 A-B, LPS vs. LPS+SB; One-way ANOVA, 






Figure 4-18 Sodium butyrate induces global upregulation of H3K9ac expression in 
activated microglia.  
(A) Immunocytochemistry analysis shows an increase in expression of H3K9ac (red) upon treatment 
with HDACi in LPS activated BV2 microglia. Lectin (green) used as a microglial marker. DAPI 
(blue) stains nuclei; n=3. Scale bars denote 50μm. (B) Average H3K9ac pixel intensity in each 
nucleus was consolidated and plotted with respect to treatment. SB treatment significantly increased 
average H3K9ac intensity/cell nuclei. >1000 cells were included from each n=3 biological 
replicates. Data is represented as median ± IQR, ****p<0.0001. One-way ANOVA, Tukey’s post 
hoc test.  
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 Sodium butyrate upregulates H3K9ac enrichment at the Il10 gene promoter 
during LPS mediated microglial activation 
After establishing that HDAC inhibition alters global H3K9ac expression patterns, we 
investigated the gene specific alteration of H3K9ac enrichment at promoters of genes 
involved in the microglial immune response. Figure 4-19 shows the optimal shearing 
efficiency of chromatin (<1000kb and >100kb) that was used for the chromatin 
immunoprecipitation assay (ChIP).  
H3K9ac enrichments are seen to peak at the promoter regions of active/induced genes close 
to their transcription start site (TSS) (Karmodiya et al., 2012). Primers were designed to 
probe approximately 100bp regions at Il10 and Fcrlb gene promoters, immediately 
downstream of the TSS, for investigating treatment-dependent changes in H3K9ac 
enrichment. The amplicons resulting from the primers of each gene were assessed by 
MFEPrimer 2.0 for specificity (Qu et al., 2012). The corresponding amplicons have been 
blasted (blat-blast t) (Kent, 2002) using UCSC genome browser with the Mouse Dec. 2011 
(GRCm38/mm10) Assembly (Chinwalla et al., 2002, Kent et al., 2002) to indicate genomic 
context of the region probed (Il10; Figure 4-20). The H3K9ac enrichment was normalized 
against H3 enrichment to account for nucleosome density at the probed promoter regions. 
Findings showed a significantly up-regulated H3K9ac/H3 enrichment at IL10 gene 
promoter upon SB-mediated HDAC inhibition in control and activated microglia (Figure 
4-21, n=3 cultures, One-way ANOVA, Tukey’s post hoc test; Control 6h (C6) vs SB + LPS 
6h (SBL6), *p=0.014; LPS 6h (L6) vs SB 6h (SB6), **p=0.007; L6 vs SBL6, *p=0.026).  
However, Fc Receptor-Like B (Fcrlb) (Figure 4-22), an IL10/STAT3 anti-inflammatory 
pathway target involved in phagocytosis, did not show significant upregulation of H3K9ac 
enrichment induced by HDAC inhibition at its gene promoter (Figure 4-23, n=3 cultures, 
115 




Figure 4-19 Chromatin shearing efficiency 
 DNA agarose gel electrophoresis displaying the efficiency of chromatin shearing for the sets of 
samples (BV2 microglial cells) used for the chromatin immunoprecipitation assay, towards probing 
H3K9ac enrichment in microglia. Gels show an optimal <1000 kb and >100 kb Chromatin shearing 
following sonication. Set 1, 2, 3 were selected for ChIP assay and further analysis. SB=Sodium 
butyrate; L: LPS; C1: Control 1h; L1: LPS 1h; SB1: SB 1h; SBL1: SB+LPS 1h; C6: Control 6h; 





Figure 4-20 Genomic context and primer specificity for Il10 ChIP-qPCR –  
 Provided is the amplicon resulting from primers probing Il10 gene promoter in ChIP-qPCR 
assay, analysed through MFEPrimer 2.0. Represented is the position of the amplicon in the 
UCSC genome browser (http://genome.ucsc.edu) against the mouse genome. The dissociation 
curve and amplification plot of the primer pair indicate specificity, and the exponential 
amplification of a single product.  
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Figure 4-21 H3K9ac/H3 enrichment increased at the Il10 promoter in activated 
microglia following HDAC inhibition using sodium butyrate  
Chromatin immunoprecipitation assay indicated an increase in H3K9ac enrichment with respect to 
nucleosome density at the Il10 gene promoter in LPS activated microglia in response to HDAC 
inhibition using SB. H3 enrichment indicating nucleosome density was observed to significantly 
increase with HDAC inhibition following LPS mediated activation for 6h. In addition, an increase 
in PolII enrichment was observed at the Il10 promoter following HDAC inhibition at 6h activation 
of microglia. Data represented as mean ± SEM; n=3 cultures; One-way ANOVA, Tukey’s post hoc 




Figure 4-22 Genomic context and primer specificity for Fcrlb in ChIP-qPCR 
 Provided is the amplicon resulting from primers probing Fcrlb gene promoter in ChIP-qPCR 
assay, analysed through MFEPrimer 2.0. Represented is the position of the amplicon in the 
UCSC genome browser (http://genome.ucsc.edu) against the mouse genome. The dissociation 
curve and amplification plot of the primer pair indicate specificity, and the exponential 
amplification of a single product.  
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Figure 4-23 H3K9ac/H3 enrichment showed an increasing trend at the Fcrlb promoter 
following HDAC inhibition using sodium butyrate  
Chromatin immunoprecipitation assay indicated an insignificant increase in H3K9ac enrichment 
with respect to nucleosome density at the Fcrlb gene promoter in LPS activated microglia in 
response to HDAC inhibition using SB. H3 enrichment indicating nucleosome density was observed 
to significantly increase with HDAC inhibition following LPS mediated activation for 6h. Data 
represented as mean ± SEM; n=3 cultures; One-way ANOVA, Tukey’s post hoc test; *p <0.05. 
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 Sodium butyrate downregulates H3K9ac enrichment at pro-inflammatory gene 
promoters during LPS mediated microglial activation  
H3K9ac enrichment at the promoters of pro-inflammatory genes TNF-α, STAT1, 
Interleukin-6 (IL-6) and Nitric Oxide Synthase 2 (NOS2) were investigated in microglia 
subjected to LPS-mediated activation for a duration of 1h and 6h in the presence of HDAC 
inhibitor, SB. Primers were designed to probe approximately 100bp regions at gene 
promoters of selected genes, immediately downstream of the TSS (Karmodiya et al., 2012), 
for investigating treatment-dependent changes in H3K9ac enrichment. The amplicons of 
every primer pair /gene were assessed by MFEPrimer 2.0 for specificity (Qu et al., 2012). 
by blast (blat) (Kent, 2002) using UCSC genome browser with the Mouse Dec. 2011 
(GRCm38/mm10) Assembly (Chinwalla et al., 2002, Kent et al., 2002) to indicate genomic 
context of the region probed (Tnf; Figure 4-24). The H3K9ac enrichment was normalized 
against H3 enrichment to account for nucleosome density at the probed promoter regions. 
 The Tumor Necrosis Factor – alpha (TNF-α) gene promoter served as a positive control 
for the H3K9ac mark as it is a primary response gene, implicated in microglial activation 
(Yarilina et al., 2008). PolII enrichment at the Tnf-α promoter served as positive control 
for assay quality (Figure 4-25C). Our study shows the significant decrease in H3K9ac/H3 
enrichment at the TNF-α promoter in response to SB treatment (Figure 4-25, n=3 cultures, 
One-way ANOVA, Tukey’s post hoc test; C6 vs SB6, *p=0.02; C6 vs SBL6, *p=0.018; L6 
vs SB6, p=0.139; L6 vs SBL6, p=0.123). H3K9ac/H3 enrichment at IL6 (Figure 4-26) and 
NOS2 (Figure 4-28) did not show a significant change upon HDAC inhibitor treatment in 
activated microglia (n=3 cultures, One-way ANOVA, Tukey’s post hoc test; Figure 4-27, 
IL6 (C6 vs SB6, p=0.992; L6 vs SBL6, p=0.136); Figure 4-29, NOS2 (C6 vs SB6, p=0.4; 
L6 vs SBL6, p=0.57). However, H3K9ac/H3 enrichment was seen to be significantly 
decreased at the STAT1 promoter (Figure 4-30) in response to SB treatment (Figure 4-
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31, n=3 cultures, One-way ANOVA, Tukey’s post hoc test; IL6 (Control 1hr (C1) vs SB 
1h (SB1), *p=0.012; C1 vs SB + LPS 1h (SBL1), *p=0.012; L1 vs SB1, *p=0.013; L1 vs 




Figure 4-24 Genomic context and primer specificity for Tnf-α in ChIP-qPCR  
 Provided is the amplicon resulting from primers probing Tnf-α gene promoter in ChIP-qPCR 
assay, analysed through MFEPrimer 2.0. Represented is the position of the amplicon in the 
UCSC genome browser (http://genome.ucsc.edu) against the mouse genome. The dissociation 
curve and amplification plot of the primer pair indicate specificity, and the exponential 
amplification of a single product.  
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Figure 4-25 H3K9ac/H3 enrichment markedly decreased at the Tnf-α promoter 
following HDAC inhibition using sodium butyrate  
Chromatin immunoprecipitation assay indicated a decrease in H3K9ac enrichment with respect to 
nucleosome density at the Tnf-α gene promoter in LPS activated microglia in response to HDAC 
inhibition using sodium butyrate. A strong enrichment of PolII was observed at the Tnfα promoter. 




Figure 4-26 Genomic context and primer specificity for Il6 in ChIP-qPCR 
 
 
Provided is the amplicon resulting from primers probing Il6 gene promoter in ChIP-qPCR assay, 
analysed through MFEPrimer 2.0. Represented is the position of the amplicon in the UCSC 
genome browser (http://genome.ucsc.edu) against the mouse genome. The dissociation curve 
and amplification plot of the primer pair indicate specificity, and the exponential amplification 
of a single product.  
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Figure 4-27 H3K9ac/H3 enrichment did not change significantly at the Il6 promoter 
following HDAC inhibition using sodium butyrate  
Chromatin immunoprecipitation assay indicated no change in H3K9ac enrichment with respect to 
nucleosome density at the Il6 gene promoter in LPS activated microglia in response to HDAC 
inhibition using sodium butyrate. Data represented as mean ± SEM; n=3 cultures; One-way 




Figure 4-28 Genomic context and primer specificity for Nos2 in ChIP-qPCR  
 
 
Provided is the amplicon resulting from primers probing Nos2 gene promoter in ChIP-qPCR 
assay, analysed through MFEPrimer 2.0. Represented is the position of the amplicon in the 
UCSC genome browser (http://genome.ucsc.edu) against the mouse genome. The dissociation 
curve and amplification plot of the primer pair indicate specificity, and the exponential 
amplification of a single product.  
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Figure 4-29 H3K9ac/H3 enrichment did not change significantly at the Nos2 promoter 
following HDAC inhibition using sodium butyrate  
Chromatin immunoprecipitation assay indicated no change in H3K9ac enrichment with respect to 
nucleosome density at the Nos2 gene promoter in LPS activated microglia in response to HDAC 
inhibition using sodium butyrate. However, there was a significant increase in nucleosome density 
in 6h LPS activated microglia following HDAC inhibition. Data represented as mean ± SEM; n=3 








Provided is the amplicon resulting from primers probing Stat1 gene promoter in ChIP-qPCR 
assay, analysed through MFEPrimer 2.0. Represented is the position of the amplicon in the 
UCSC genome browser (http://genome.ucsc.edu) against the mouse genome. The dissociation 
curve and amplification plot of the primer pair indicate specificity, and the exponential 




Figure 4-31 H3K9ac/H3 enrichment markedly decreased at the Stat1 promoter 
following HDAC inhibition using sodium butyrate  
Chromatin immunoprecipitation assay indicated a decrease in H3K9ac enrichment with respect to 
nucleosome density at the Stat1 gene promoter in LPS activated microglia in response to HDAC 
inhibition using sodium butyrate. Data represented as mean ± SEM; n=3 cultures; One-way 
ANOVA, Tukey’s post hoc test; *p <0.05. 
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 Sodium butyrate downregulates gene expression of pro-inflammatory 
transcription factor Stat1 
There have been various accounts of HDAC inhibitors suppressing pro-inflammatory 
genes and inducing an anti-inflammatory effect in microglial cells (Kannan et al., 2013, 
Huuskonen et al., 2004, Faraco et al., 2009, Suh et al., 2010, Chen et al., 2007). Further 
confirmation of the anti-inflammatory potential of HDAC Class I and II inhibition was the 
reduction in gene expression of pro-inflammatory genes probed in this study. HDAC 
inhibition decreased Stat1 gene expression significantly in activated microglia (Figure 4-
32, n=4 cultures, Two-way ANOVA, Tukey’s post hoc test; C3 vs. L3 *p=0.26; C6 vs. L6, 








Figure 4-32 Gene expression of Stat1 decreased in activated microglia in response to 
sodium butyrate treatment.  
Quantitative-PCR showed that gene expression of Stat1 increased in response to LPS 3h and 6h 
treatment (black), which is rescued by SB treatment (blue). Data represented as mean ± SEM; n=4; 





 Sodium butyrate downregulates protein expression of pro-inflammatory 
transcription factor STAT 1 and its activated form pSTAT1  
These results were further validated in western blot analysis of pSTAT1 and STAT1 
proteins which showed a downregulation of pSTAT1 and STAT1 in response to SB 
treatment (Figure 4-33 A) as quantified (Figure 4-33 B-C, n=3, Two-way ANOVA, 
Tukey’s post hoc test; pSTAT1 (C6 vs L6, *p=0.023; L6 vs SB6, **p=0.009; L6 vs SBL6, 
*p=0.016), STAT1 (C6 vs L6, p=0.055; L6 vs SB6, **p=0.008; L6 vs SBL6, *p=0.017). 
This decrease was accompanied by a reduction in levels of the activated form pSTAT1 
(Tyr 701) as seen in BV2 and primary microglia through immunofluorescence staining and 
confocal analysis (Figure 4-34, 35).   
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Figure 4-33 STAT1 and pSTAT1 protein levels are concomitantly decreased in 
activated microglia in response to SB treatment 
Representative blot of protein expression showed a decrease in pSTAT1 and total STAT1 protein 
in activated microglia (for 6h) in response to activated microglia without SB treatment, with respect 
to corresponding β-actin. Note that there was no change in protein expression in microglia exposed 
to LPS for 1h. (A) Quantification of the western blot with densitometric analysis of pSTAT1 and 
STAT1 proteins are normalised to corresponding β-actin and represented as fold change. Data 




Figure 4-34 Increase in pSTAT1 protein expression in activated microglia was 
suppressed by sodium butyrate treatment  
Immunofluorescence staining displayed an upregulation of pSTAT1 in response to LPS mediated 
microglial activation. The pSTAT1 (red) expression was suppressed in the presence of SB treatment. 
BV2 microglial cells are stained with lectin (green) which is used as microglial marker. DAPI (blue) 





Figure 4-35 Increase in pSTAT1 protein expression in LPS activated primary 
microglia was suppressed by sodium butyrate treatment  
Immunofluorescence staining displayed an upregulation of pSTAT1 in response to LPS mediated 
microglial activation in primary microglial cultures. The pSTAT1 (red) expression was suppressed 
in the presence of SB treatment. Primary microglial cells stained with CD11b (green) used as 
microglial marker. DAPI (blue) stains nuclei; n=3. Scale bars denote 20μm. 
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 HDAC inhibitor, sodium butyrate promotes gene and protein expression of 
anti-inflammatory mediator Il10  
In contrast to STAT1, IL10 was found to be upregulated in LPS activated microglia upon 
SB treatment, as observed in gene expression (Figure 4-36, n=4 cultures, Two-way 
ANOVA, Tukey’s post hoc test; L1 vs SBL1, *p<0.0001; SB1 vs SBL1, **p=0.006; L6 vs 
SBL6, *p=0.035), and protein expression in BV2 (Figure 4-37) and primary microglia 
(Figure 4-38) respectively. The changes in gene transcription of STAT1 and IL10 in 
activated microglia treated with SB indicated the possible anti-inflammatory mechanism 
of action of this drug via these gene loci. The increase in gene transcription of IL10 in 
microglia following HDAC inhibition can be correlated to the increased chromatin 








Figure 4-36 Gene expression of Il10 increased in activated microglia in response to 
sodium butyrate treatment.  
Quantitative-PCR showed that gene expression of Il10 increases in response to SB treatment (blue) 
in activated microglia. Data represented as mean ± SEM; n=4; Two-way ANOVA, Tukey's post hoc 








Figure 4-37 IL10 protein expression in activated microglia was enhanced by sodium 
butyrate treatment  
Immunofluorescence staining displayed an upregulation of IL10 (red) in response to SB treatment. 
BV2 microglial cells are stained with lectin (green) which is used as microglial marker. DAPI (blue) 





Figure 4-38 IL10 protein expression in activated primary microglia was enhanced by 
sodium butyrate treatment  
Immunofluorescence staining displayed an upregulation of IL10 (red) in response to SB treatment. 
Primary microglial cells are stained with CD11b (green) which is used as microglial marker. DAPI 




Delineating the signalling pathway in activated microglia elicited in response to 
sodium butyrate-mediated HDAC inhibition 
 HDAC inhibitor, sodium butyrate promotes gene expression of Stat3 and 
induces an increase in the number of pSTAT3 nuclear bodies 
SB treatment increased Stat 3 gene expression levels in microglia (Figure 4-39, n=4 
cultures, Two-way ANOVA, Tukey’s post hoc test; C1 vs SB1, C3 vs SB3, C6 vs SB6, 
****p<0.0001; L1 vs SBL1, **p=0.004; L3 vs SBL3, ****p<0.0001; C6 vs L6, *p=0.037; 
L6 vs SBL6, **p=0.006). An investigation into the activated form of 
STAT3 – phosphorylated STAT3 (Y705) – led us to observe a punctate nuclear 
localization of pSTAT3 (Y705) in microglia visually similar to speckles or interchromatic 
granule clusters (Sleeman and Trinkle-Mulcahy, 2014), which have been identified as 
pSTAT3 nuclear bodies in previous studies (Herrmann et al., 2004) (Figure 4-40). Number 
of nuclear bodies was visually and quantitatively confirmed to be drastically increased 
upon HDAC inhibition, when compared to control and activated microglia (Figure 4-41, 
>40 cells/treatment spread over n=3, One-way ANOVA, Dunn’s post hoc test; C vs SB, 
L6 vs SBL6, ****p<0.0001; L1 vs SBL1, ***p=0.0006)). It has been shown that activated 
pSTAT3 in the nuclear bodies co-localizes with transcriptionally active regions (Herrmann 
et al., 2004). These findings suggest a potential increase in pSTAT3 binding to specific 








Figure 4-39 Stat3 gene expression was upregulated in response to treatment with SB 
An increase in Stat3 gene expression was observed in activated microglia in response to HDAC 
inhibition using sodium butyrate. Data represented as mean ± SEM; n=4; Two-way ANOVA, 





Figure 4-40 Increase in pSTAT3 nuclear bodies in activated microglia in response to 
SB treatment 
pSTAT3 (Y705) nuclear bodies increase in response to SB treatment when compared to control and 
LPS activated microglia. Representative image depicting the increased prevalence of pSTAT3 
nuclear bodies in microglia in response to SB. Lectin (green) marks microglia; DAPI (blue) marks 
nuclei and pSTAT3 localization is presented as two LUTs of red and gradient. Scale bars denote 








Figure 4-41 Quantification of pSTAT3 nuclear bodies in activated microglia in 
response to SB treatment depicts an increase 
Quantification of nuclear bodies/cell nucleus (red) identified above threshold with respect to 
treatment group. Data derived from >40 cell nuclei spread over n=3; represented as median ± IQR; 





 Sodium butyrate upregulates expression of pSTAT3 downstream targets 
induced via IL10 signalling 
IL10 induces anti-inflammatory signalling using STAT3 as a mediator in various cell types 
including microglia (Couper et al., 2008, Strle et al., 2002). Thus, a STAT3 mediated anti-
inflammatory (Murray, 2006a) pathway might be in effect during HDAC inhibition in 
activated microglia. These results suggest that inhibition of HDAC class I, II induces 
neuroprotective microglial behaviour over the neurotoxic pro-inflammatory response, 
through a pathway involving IL10/STAT3 axis of signalling. Such an induction of an anti-
inflammatory signalling pathway could be regulating microglia towards a neuroprotective 
phenotype, thus also being a possible mechanism for the therapeutic ability of HDAC 
inhibitors.  
To test the induction of IL10-STAT3 pathway by SB, expression levels of downstream 
targets of IL10-STAT3 axis were analysed. Downstream target genes of IL10/STAT3 
signalling were selected from matched RNA-seq and CHIP-seq studies (against STAT3) 
performed in macrophages upon the induction with IL10 to find members of the anti-
inflammatory response. (Hutchins et al., 2012). Among the targets revealed by this dataset 
(consisting of STAT3 targets specific to IL10 signalling), genes Socs1, MafB, Il4ra, Fcrlb, 
and Itpr1 were selected for further analysis due to their roles in promoting the microglial 
anti-inflammatory phenotype. Gene expression analysis revealed the upregulation of 
selected genes following SB treatment, confirming the involvement of IL10-STAT3 anti-
inflammatory pathway in the mechanisms of action of HDAC inhibitor SB in microglial 
activation. (Figure 4-42, n=4 cultures, Two-way ANOVA, Tukey’s post hoc test; Socs1 
(C1 vs SB1, *p=0.022; C3 vs SB3 ***p=0.0008; C3 vs SBL3, **p=0.05; C6 vs SB6, 
***p=0.0004; C6 vs SBL6, *p=0.011; C3 vs L3 *p=0.26; C6 vs L6, L6 vs SBL6, 
****p<0.0001); Mafb (C1 vs SB1, *p=0.013; L1 vs SBL1, **p=0.004; C3 vs SB3, 
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**p=0.001; L3 vs SBL3, *p=0.015; C6 vs SB6, **p=0.002; L6 vs SBL6, *p=0.028) Il4ra 
(C3 vs SB3, ****p<0.0001; L3 vs SB3, *p=0.018) Fcrlb (L1 vs SBL1, *p=0.047; C3 vs 
SB3, *p=0.037; L3 vs SBL3, *p=0.045; C6 vs SB6, ***p=0.0007; L6 vs SBL6, *p=0.035) 
Itpr1 (C1 vs SB1, **p=0.004; L1 vs SBL1, **p=0.007; C3 vs SB3, **p=0.003; L3 vs SBL3, 





Figure 4-42 Gene expression of the downstream targets of IL10/STAT3 pathway was up-
regulated in response to HDAC inhibition via SB treatment  
Gene expression analysis displayed an upregulation of downstream targets of the IL10/STAT3 anti-
inflammatory pathway, i.e. Itpr1, Mafb, Il4ra, Fcrlb and Socs1 upon HDAC inhibition by SB, 
confirming the induction of IL10/STAT3 anti-inflammatory signalling pathway by sodium butyrate. 
Histogram represents gene expression fold change (through qPCR) in response to SB treatment; 
with treatment groups including untreated control, LPS 1, 3, 6hrs, with or without SB respectively. 
Data represented as mean ± SEM; n=4; Two-way ANOVA; Tukey’s post hoc test, *p <0.05, ** 
p<0.01; ***p<0.001; ****p<0.0001. 
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 Sodium butyrate downregulates pro-inflammatory gene signalling in activated 
microglia 
Consequently, pro-inflammatory genes Tnf-α, Nos2, Il-6, and Irf-1 were seen to be 
downregulated in activated microglia upon SB mediated HDAC inhibition (Figure 4-43, 
n=4 cultures, Two-way ANOVA, Tukey’s post hoc test; Tnf-α (C1 vs L1, ****p<0.0001; 
L1 vs SBL1, ***p=0.0008; C3 vs L3, ***p=0.0005; L3 vs SBL3, *p=0.034; C6 vs L6, 
*p=0.012; L6 vs SBL6, p=0.11) Nos2 (C3 vs L3, *p=0.01; C6 vs L6, ***p=0.0002; L6 vs 
SBL6, *p=0.01) Il6 (C6 vs L6, *p=0.015) Irf1 (C1 vs L1, **p=0.002; C3 vs L3, **p=0.004; 








Figure 4-43 Gene expression of pro-inflammatory genes significantly decreased in 
activated microglia in response to SB treatment 
Quantitative PCR analysis showed that gene expression of pro-inflammatory genes Tnf-α, Nos2, Il6 
and Irf1 was induced in response to LPS treatment, which was then suppressed by corresponding 
SB treatment. Histogram represents gene expression fold change (through qPCR) in response to SB 
treatment; with treatment groups including untreated control, LPS 1, 3, 6hrs, with or without SB 
respectively. Data represented as mean ± SEM; n=4; Two-way ANOVA; Tukey’s post hoc test.  






Primarily, microglial cells protect the brain during pathogenesis by eliciting an immune 
response to infection, injury or ischemia, clearing the debris of the aftermath through 
phagocytosis and releasing neurotrophic factors to aid in tissue regeneration (Block et al., 
2007, Hanisch and Kettenmann, 2007, Paolicelli et al., 2011). However, chronic microglial 
activation, associated with neuroinflammation has been shown to exacerbate 
neurodegeneration in several neuropathologies, including ischemic stroke (Jin et al., 2010, 
Block et al., 2007, Chhor et al., 2013, Heneka et al., 2015, Dheen et al., 2007).  
As shown by the Immunological Genome Project, microglial cells have a unique 
transcriptome specialized to suit the brain environment (Emmanuel et al., 2012). The 
specialized immune response of microglia is regulated by specific epigenetic mechanisms 
which include histone modifications. Hence, this study was aimed to explore histone 
modification based epigenetic regulation of microglial activation. In particular, we have 
studied H3K9ac, a histone mark involved in promoter regulation at transcriptionally active 
genes. Starting with characterizing the global expression of H3K9ac in microglia, in the 
heathy brain during development, we analysed its expression pattern in activated microglia 
in rodent models of ischemic stroke and bacterial infection. Next, the regulators of H3K9ac 
i.e. HDACs were pharmacologically modulated to demonstrate their neuroprotective effect 
in ischemic stroke. Interestingly, HDAC inhibitor- SB treatment in ischemic mice switched 
the activation phenotype of microglia from pro-inflammatory towards anti-inflammatory. 
This is the first study to investigate the effect of HDAC inhibition on microglial activation 
in vivo. 
Further investigation into the molecular basis of microglia-mediated neuroprotection 
revealed that SB induces epigenetic changes in H3K9ac enrichment on promoters of select 
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genes crucial to the microglial inflammatory response. The changes in promoter H3K9ac 
levels were further reflected in the transcriptional outcome of genes Il10, Stat1 and Tnf-α.  
Subsequently, a SB-induced transcriptional upregulation of genes participating in the IL10-
STAT3 anti-inflammatory axis was observed. This was accompanied by a suppression of 
several pro-inflammatory genes involved in microglial activation. Even though SB 
increases global chromatin accessibility through the upregulation of histone acetylation, 
the interesting aspect is that the overall effect of SB-mediated HDAC inhibition culminates 
into the selective suppression of pro-inflammatory genes while up-regulating an IL10 anti-
inflammatory pathway, ultimately pushing microglia towards neuroprotective behaviour. 
The following section discusses in detail, the results presented in the study in a 
chronological order of their mention.  
 H3K9ac expression levels in amoeboid microglia decreases upon ramification 
Amoeboid microglia found in the brains of postnatal pups gradually transform into 
ramified microglia during development. H3K9ac levels were highly enriched in amoeboid 
microglia during development, gradually diminishing upon its ramification. Increased 
global H3K9ac levels point to larger subsets of genes, which are functional in amoeboid 
microglia. Indeed, amoeboid microglia have been shown to support the developing brain 
by carrying out diverse functions to promote neuronal development and survival (Nayak et 
al., 2014). Microglia aid in lineage determination of neuronal subsets and neuronal circuit 
formation through the release of region specific neurotrophic factors (Ueno et al., 2013, 
Trang et al., 2011). During the developmental process, which includes a massive 
programmed cell death of neurons with defective differentiation and migration, microglial 
cells can induce neuronal apoptosis (Wakselman et al., 2008) and then carry out 
phagocytosis via mediators like TREM-2, and CD-47 (Takahashi et al., 2005, Li et al., 
2012a). In fact, microglia are also involved in synaptic signalling with neurons through 
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fractalkine and complement dependent pathways and continuously assist in synaptic 
pruning and maintenance through the release of neurotrophic factors specific to brain 
region to ensure normal neurodevelopment (Paolicelli et al., 2011, Stevens et al., 2007, 
Schafer et al., 2012). The increased levels of H3K9ac in microglia could be indicating 
several active genes in amoeboid microglia that are silenced after microglial ramification.  
Nevertheless, upregulated H3K9ac in amoeboid microglia, as opposed to ramified 
microglia points to different epigenetic regulatory pathways operating in both phenotypes. 
Understanding these differences is crucial in order to employ epigenetic strategies and 
pharmaceutic interventions to regulate microglial behaviour in developmental scenarios.  
 Upregulation of H3K9ac expression levels is a universal attribute of microglial 
activation 
Although H3K9ac expression was found to be downregulated in ramified microglia, an 
upregulation of global H3K9ac expression levels was observed when microglia were 
activated by the pathological stimuli i.e. ischemia and infection. In this study, it was seen 
that both, ischemia caused by MCAO and bacterial infection caused by LPS treatment, 
upregulated global H3K9ac expression levels in activated microglia in vivo. These results 
indicate that upregulation of H3K9ac levels is associated with microglial activation, 
irrespective of origin of stimuli.  
The immune response depends on the transcription of a number of secondary response 
genes involving transcription factors and other molecules which act in concert with 
epigenetic regulators such as histone marks and chromatin modifiers, to elicit altered gene 
expression (Lim et al., 2010, Smale and Natoli, 2014). Global H3K9ac upregulation in 
activated microglia could indicate the epigenetic activation of secondary and tertiary 
response genes, which are involved in eliciting the microglial pro-inflammatory response. 
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These results further indicate that manipulation of H3K9ac may modulate pro-
inflammatory response of activated microglia. 
 Neuroprotective effect of the HDAC inhibitor- sodium butyrate, in ischemia, is 
elicited via epigenetic regulation of microglia in vivo 
Currently, several HDAC inhibitors are amidst various clinical and preclinical trials for the 
treatment of cancers, and neurological diseases including Alzheimer’s disease, 
Huntington’s disease, dementia and stroke (Kim et al., 2007, Dokmanovic et al., 2007, 
Montalvo-Ortiz et al., 2014, Falkenberg and Johnstone, 2014). However, there is still 
controversy about the effect of HDAC inhibitors on microglia activation, with different 
groups reporting opposing trends based on variation in HDAC inhibitors and experimental 
treatment (Kaminska et al., 2016). Previous studies have shown HDAC inhibitors to be 
neuroprotective in ischemic stroke (Kim et al., 2007, Xuan et al., 2012). The present study 
is the first to provide in vivo evidence to suggest that SB, an HDAC inhibitor, exerts its 
neuroprotective effect in ischemic stroke by regulating epigenetic mechanisms which 
contribute to transformation of microglial phenotype from pro-inflammatory to anti-
inflammatory. SB-treated mice displayed a decreased number of H3K9ac positive 
microglia, and downregulated expression of the pro-inflammatory mediators such as TNF-
α and NOS2, and upregulated expression of IL10, an anti-inflammatory cytokine, in 
activated microglia in striatum, cortex and hippocampus of the ischemic brain, concomitant 
to decreased neurodegeneration. Thus, this study lends support to the therapeutic potential 
of HDAC inhibitors, specifically SB, in eliciting anti-inflammatory microglial activation 
in vivo, thereby aiding in neuroprotection during ischemic stroke. Furthermore, 
prophylactic treatment with SB to switch microglial phenotype at an early stage of 
ischemia, has a potential to counteract microglia-mediated neurotoxicity early and prevent 
further inflammation and neurodegeneration in later stages of the disease.  
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 Sodium butyrate suppresses pro-inflammatory genes while up-regulating anti-
inflammatory genes in LPS activated microglia 
In vitro studies were carried out to probe the immediate effect of SB treatment on microglia 
and the molecular basis of the in vivo findings, which showed SB to elicit an anti-
inflammatory microglia phenotype in the ischemic stroke brain. In vitro findings show 
evidence of SB-mediated HDAC inhibition to specifically downregulate the expression of 
a number of pro-inflammatory genes including Tnf-α, Nos2, Il-6, Irf-1, and Stat1 while 
upregulating expression of anti-inflammatory genes Il10 and Stat3. These results 
corroborate the results published by earlier studies, which demonstrate the suppression of 
pro-inflammatory mediators through HDAC inhibition in microglia (Kannan et al., 2013, 
Huuskonen et al., 2004, Faraco et al., 2009, Suh et al., 2010, Chen et al., 2007, Xuan et al., 
2012). 
One of the stark effects of SB treatment is the hyper-acetylation (of H3K9ac) in the 
microglial genome, visually and quantitatively assessed using immunofluorescence. 
Chromatin hyper-acetylation is concomitant with increased accessibility as there is a 
decrease in the strength of DNA histone binding (Bannister and Kouzarides, 2011). 
However, the most crucial aspect of hyper-acetylation that appears to dictate the overall 
effect extended on the regulatory systems of the cell is the genomic context of increased 
accessibility i.e. the selective genomic regions that were hyper-acetylated and as a 
consequence had increased transcriptional activity (Rafehi et al., 2014). Our results also 
identified gene promoters Tnfα and Stat1 that were hypo-acetylated, which extended to a 
transcriptional silencing effect. Indeed, previous studies have also identified 
pharmacological HDAC inhibition to variably regulate H3K9ac enrichment and 
transcription in a gene specific manner (Rafehi et al., 2014).  
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 Sodium butyrate alters H3K9ac enrichment at promoters of pro- and anti-
inflammatory genes in microglia 
With respect to genomic context of hyper-acetylation, the upregulation of H3K9ac 
enrichment observed on the promoter of the anti-inflammatory gene, Il10 in response to 
HDAC class I and II inhibition by SB suggests an HDAC-dependent H3K9ac regulation at 
Il10 promoter in activated microglia. More so, the increased H3K9ac was accompanied by 
increased expression of Il10 indicating the ability of SB to epigenetically regulate 
transcription of Il10 in microglia. In contrast, the suppressed expression of Tnf-α and Stat1 
in activated microglia is supported by the downregulated H3K9ac at these gene promoters, 
indicating that SB, brings about the epigenetic downregulation of Tnf-α and Stat1 in 
activated microglia. A plausible reason for the decreased H3K9ac enrichment, even though 
HDAC inhibition increases genomic acetylation, could be that the recruitment of HATs to 
these promoters is disrupted. Indeed, ChIP-seq studies of H3K9/K14ac upon HDAC 
inhibitor treatment showed that a substantial number of genes were down-regulated with 
promoter deacetylation upon HDAC inhibitor treatments and the promoter deacetylation 
was associated to the loss of binding of EP300/CREBBP, a HAT complex, at these gene 
promoters (Rafehi et al., 2014). Overall, HDAC inhibition promotes anti-inflammatory 
microglia phenotype through selective modulation of H3K9ac at specific promoters, which 
may contribute to neuroprotection in neuropathologies. 
 Sodium butyrate might be utilizing the IL10/STAT3 anti-inflammatory 
cascade to suppress pro-inflammatory gene expression 
Keeping in context the ability of IL10 to regulate neurogenesis (Pereira et al., 2015), our 
results highlight that HDAC inhibitor extends neuroprotection in the ischemic brain 
through the induction of the anti-inflammatory mediator IL10, in microglia. Our results 
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reflect the findings that SB treatment stimulates neurogenesis in ischemic stroke (Kim et 
al., 2009).  
IL10 has been shown to protect cortical neurons from damage through activation of PI-3 
kinase and STAT3 signalling pathways in neurons (Sharma et al., 2011). The IL10 
signalling pathway suppresses TLR-induced inflammation in T-cell, B-cell subsets, 
macrophages and dendritic cells by activating STAT3 via JAK1-dependent 
phosphorylation (Weber-Nordt et al., 1996, Williams et al., 2004, Murray, 2006b), as also 
seen in microglia (Sawada et al., 1999, Strle et al., 2002). Further, STAT3 mediates the 
anti-inflammatory response indirectly through inducing other repressors, which suppress 
TLR-induced gene expression (Murray, 2006a, Murray, 2006b). The increase in 
intracellular STAT3 in response to SB in activated microglia in the present study, could be 
due to the upregulation of IL10 signalling (Weber-Nordt et al., 1996) thus inducing the 
anti-inflammatory response. The upregulation of IL10/STAT3 target genes such as Socs1, 
Mafb, Itpr11, Fcrlb and Il4ra, provide an in vitro evidence of the IL10/STAT3 signalling 
pathway being induced by SB towards the anti-inflammatory microglial phenotype.  
In particular, the upregulation of Socs1 draws special interest, as SOCS1 has been known 
to downregulate several proteins in the TLR/IFN signalling pathways (Yoshimura et al., 
2007, Qin et al., 2006). It is likely that the repression of pro-inflammatory genes observed 
in our study is being carried out by the repressive effect of SOCS1 upregulation. SOCS1 
could be one of many repressors of pro-inflammatory signalling that are elicited through 
the IL10/STAT3 anti-inflammatory pathway. The anti-inflammatory response genes 
specially elicited through SB treatment which supress pro-inflammatory signalling through 
direct or indirect mechanisms, is a potential area for further study.  
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6 Conclusion 
Ischemic stroke is a common cause for neurological disability that affects people 
worldwide. Although there is no effective treatment strategy for recovery, rehabilitation 
i.e. to get back to normal life as much as possible while preventing additional stroke attacks 
and tissue damage, can improve the survival and functions of the patients. In recent years, 
pharmacogenomic research groups have explored new avenues of epidrugs, their discovery 
based on histone modifications and non-coding RNAs engineering, for the treatment of 
various neurological diseases including ischemic stroke.  
Signalling pathways involve transcription factors, which act in concert with epigenetic 
regulators such as histone marks and chromatin modifiers, to elicit altered gene expression 
(Lim et al., 2010, Smale and Natoli, 2014). This study reveals that histone modifications, 
in particular global H3K9ac modulations, contribute to microglial phenotype 
diversification by altering its expression of pro- and anti-inflammatory genes in the 
ischemic stroke brain. Furthermore, the upregulation of global H3K9ac observed in 
activated microglia in response to ischemic stroke and LPS treatment in vivo, indicates the 
epigenetic activation of specific genes involved in its pro-inflammatory response.  
This study further demonstrates a potential epigenetic mechanism, by which HDAC Class 
I and II inhibitor, SB, through gene specific modulation of H3K9ac enrichment, promotes 
anti-inflammatory genes involved in IL10-STAT3 signalling while suppressing pro-
inflammatory genes such as Tnf-α, Stat1 during microglial activation (Figure 6-1). A 
functional link between SB-induced changes in chromatin accessibility, and the neurotoxic 
to neuroprotective behaviour switch of microglia can enable the therapeutic manipulation 
of the Tnfα, Stat1, and Il10 gene promoters in activated microglia. In the context of 
ischemia, such epigenetic mechanisms, which are crucial to microglial activation can be 
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therapeutically targeted towards shifting the microglial phenotype from neurotoxic to 
neuroprotective, aiding in neuroprotection in the ischemic brain. 
 
 
Figure 6-1 Conceptual summary.  
External stimuli such as Lipopolysaccharide (LPS) or ischemia induces pro-inflammatory gene 
transcription at promoters (TNF-α, STAT1 shown here), where excessive release of pro-
inflammatory mediators might exacerbate neurodegeneration. In contrast, (a) treatment with sodium 
butyrate (SB) sequesters HDACs and allows HATs to acetylate Il10 promoter, upregulating 
promoter H3K9ac, which contributes to the observed increase in Il10 gene transcription and protein 
levels. (b) Increased extracellular IL10 is known to promote neurogenesis. IL10 can also induce the 
IL10/STAT3 anti-inflammatory signalling pathway in microglia. (c) Intracellular STAT3 activated 
by IL-10/JAK1 dependent phosphorylation, induces the expression of IL10/STAT3 downstream 
targets and anti-inflammatory response genes (AIRs)-Fcrlb, Il4ra, Itpr1, MafB and Socs1 (d). 
Overall, the transcription of several pro-inflammatory genes including Stat1, Tnf-α is suppressed. 
(e) Our results show lowered promoter acetylation (H3K9ac) at the Tnf-α, Stat1 promoters, 
supporting the observed loss in transcriptional activity. Thus, the upregulation of IL10 via sodium 
butyrate in microglia assists in promoting neurogenesis while switching microglial phenotype from 










7 Significance and future directions 
This study is the first to evaluate histone modifications as epigenetic regulators of 
microglial activation and to show that H3K9ac modulations are a universal trait of 
microglial activation. Moreover, this study provides the first in vivo analysis to implicate 
microglia as a mediator in the therapeutic benefit elicited by HDAC inhibition in ischemic 
stroke. Modulations of H3K9ac levels via HDACs have a direct effect on the 
transcriptional program in activated microglia, effecting its pro- and anti-inflammatory 
phenotypes. The knowledge of HDAC-dependent epigenetic regulation of H3K9ac can be 
applied to facilitate controlled microglial activation and to form a better therapeutic 
strategy for treating microglia-mediated neuroinflammation in various neuropathological 
conditions including ischemic stroke.  
Although this study unravels a novel epigenetic mechanism of microglial activation in the 
ischemic brain, certain unanswered questions identified through this study merit further 
investigation. The in vivo neuroprotective ability of HDAC inhibitors through altering 
microglial behaviour needs to be further evaluated post ischemia, at later time points in 
disease progression, to find the most beneficial time window for intervention. Moreover, 
in order to understand the complex stroke pathology and other multifactorial 
neurodegenerative conditions, it is important to investigate the role of other glial cell types 
which interact to aid in disease progression, tissue repair and regeneration.  
HDAC inhibitors have different mechanisms to regulate cell-specific functions, which 
eventually orchestrate cellular behaviour to aid in coordinated neurogenesis and repair, as 
it has been identified by previous studies (Kim et al., 2007, Dokmanovic et al., 2007, 
Montalvo-Ortiz et al., 2014, Falkenberg and Johnstone, 2014). The immediate changes of 
SB treatment in microglia which we have identified in vitro, will need to be established in 
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vivo, alongside immediate effects on the function of other cell types such as astrocytes, 
oligodendrocytes, neurons and even endothelial and ependymal cells which make up the 
brain parenchyma. For instance, SB treatment may also lead to a transient hyper-
acetylation in other cell types (neuroglia) of the brain which could influence their 
functioning and be contributing to neuroprotection in long term prognosis.  
In addition, it will be of much interest to evaluate, whether HDAC inhibitors can reduce 
microglia mediated permeability of the BBB following ischemic stroke, and how that might 
contribute to disease progression, and influence neuroinflammation and disease outcome 
post ischemia.  
The histone modifications based genomic effects of HDAC inhibition itself might be 
manifold. Mechanistically, a ChIP-seq of H3K9ac and a comparative analysis of the 
transcriptome by an RNA-seq in response to HDAC inhibitor treatments will elucidate the 
genome wide epigenetic changes that drive microglial phenotype diversification in 
neuropathological conditions during HDAC inhibition. This study has demonstrated 
changes in H3K9ac at key gene promoters in activated microglia in response to SB. These 
changes could also span to non-coding RNAs which might include another set of epigenetic 
regulators whose transcription is altered by the genomic hyper-acetylation.  
Pan-HDAC inhibitors, even though neuroprotective, face a problem of non-specificity in 
their molecular targets, as they acetylate histone and non-histone substrates (Akimova et 
al., 2012). The next step to further this study will be to investigate the epigenetic regulation 
of Il10 in depth to identify the specific HDAC that functions on the Il10 promoter; followed 
by using specific HDAC inhibitors to target histone acetylation at the Il10 promoter. This 
approach will be critical to limit side effects of HDAC inhibitor therapy in microglia and 
other cell types in the brain.  
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Recognizing the HDAC dependent regulation in microglia is a crucial step towards 
developing holistic epigenetic therapeutics with limited neurological side effects. With the 
advent of HDAC inhibitors entering clinical trials, the findings in this study highlight the 
immense potential of HDAC inhibitors in the treatment of microglia mediated 
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